menu
    • menu
    [{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Yosemite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Lomond Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Lomond Therapeutics \/ Yosemite Capital","highestDevelopmentStatusID":"6","companyTruncated":"Lomond Therapeutics \/ Yosemite Capital"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Lomond Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Lomond Therapeutics \/ Deerfield Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Lomond Therapeutics \/ Deerfield Management Company"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"||CD23\/CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"APR-1051","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sotorasib","moa":"||RAS-PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vividion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Loncastuximab Tesirine","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"AK138D1","moa":"HER3","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Regorafenib","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"||Hydrolytic enzyme","graph1":"Oncology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BTG Specialty Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specialty Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orsenix","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Orsenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orsenix \/ Syros Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Orsenix \/ Syros Pharmaceuticals"},{"orgOrder":0,"company":"Australasian Leukaemia And Lymphoma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Australasian Leukaemia And Lymphoma Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Australasian Leukaemia And Lymphoma Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Australasian Leukaemia And Lymphoma Group \/ Inapplicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"||EEF2","graph1":"Oncology","graph2":"Phase I","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Citius Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Citius Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||MET\/VEGFR\/AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Syros Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Glofitamab","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"PARP-1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"Athenex","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Collaboration","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Merck & Co"},{"orgOrder":0,"company":"Fulgent Pharma","sponsor":"Fulgent Genetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Fulgent Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fulgent Pharma \/ Fulgent Genetics","highestDevelopmentStatusID":"6","companyTruncated":"Fulgent Pharma \/ Fulgent Genetics"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Boryeong","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cytotoxic Drug","year":"2023","type":"Licensing Agreement","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Boryeong","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Boryeong"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Funding","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PanTher Therapeutics","sponsor":"Catalyst Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Series A Financing","leadProduct":"Paclitaxel","moa":"Microtubule depolymerization","graph1":"Oncology","graph2":"Phase I","graph3":"PanTher Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"PanTher Therapeutics \/ Catalyst Health Ventures","highestDevelopmentStatusID":"6","companyTruncated":"PanTher Therapeutics \/ Catalyst Health Ventures"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomedics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomedics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunomedics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomedics \/ Inapplicable"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||JAK1\/JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ONCOtherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ONCOtherapeutics","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"||JAK1\/JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"ONCOtherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ONCOtherapeutics \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"ONCOtherapeutics \/ Incyte Corporation"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Lurbinectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaMar \/ Immedica Pharma","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Immedica Pharma"},{"orgOrder":0,"company":"Megalith Pharmaceuticals","sponsor":"Radiance Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"RB-164","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Megalith Pharmaceuticals","amount2":1.1699999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Undisclosed","sponsorNew":"Megalith Pharmaceuticals \/ Radiance Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Megalith Pharmaceuticals \/ Radiance Biopharma"},{"orgOrder":0,"company":"Adcendo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ADCE-T02","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adcendo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adcendo \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Lidds","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Lidds","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lidds \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lidds \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BioNova Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sutro Biopharma \/ BioNova Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ BioNova Pharmaceuticals"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Cowen"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Baillie Gifford","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Baillie Gifford","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Baillie Gifford"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Cowen"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"STRO-001","moa":"CD74","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||G-CSF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Assertio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assertio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glatiramer Acetate","moa":"MHC-II","graph1":"Oncology","graph2":"Phase I","graph3":"Kinimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kinimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinimmune \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Givastomig","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Givastomig","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"CT-0508","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Sesen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sesen Bio \/ Carisma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sesen Bio \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ALTA2618","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alterome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"||EZH1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"ENGOT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ ENGOT","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ ENGOT"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ The Institute of Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Sixth element capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Sixth element capital","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Sixth element capital"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Funding","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tasurgratinib Succinate","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Inapplicable"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ National Cancer Institute"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"QSAM Biosciences","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Samarium-153 DOTMP","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"QSAM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"QSAM Biosciences \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"QSAM Biosciences \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ XOMA","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ XOMA"},{"orgOrder":0,"company":"Zion Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"ZN-A-1041","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Enteric Coated","sponsorNew":"Zion Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Hoag Memorial Hospital Presbyterian","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Hoag Memorial Hospital Presbyterian"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Quadriga BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"QBS10072S","moa":"SLC7A5","graph1":"Oncology","graph2":"Phase I","graph3":"Quadriga BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quadriga BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quadriga BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"HypoSpray Pharma","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Oncology","graph2":"Phase I","graph3":"HypoSpray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HypoSpray Pharma \/ Nascent Biotech","highestDevelopmentStatusID":"6","companyTruncated":"HypoSpray Pharma \/ Nascent Biotech"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"VCN-01","moa":"Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"WPD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"WPD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Chimeric","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Chimeric","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ Chimeric"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Texas Children\u2019s Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpicentRx \/ Texas Children\u2019s Hospital","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Texas Children\u2019s Hospital"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Midatech Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Midatech Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ AstraZeneca"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Datopotamab Deruxtecan","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Monomethyl Auristatin E","moa":"EphA5 MMAE","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MBrace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MBrace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"P-MUC1C-ALLO1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Astellas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Astellas Pharma"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ BofA Securities"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Zymeworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Zymeworks","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Zymeworks"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||ErbB2","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dizal Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eoc Pharma","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eoc Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eoc Pharma \/ Immutep","highestDevelopmentStatusID":"6","companyTruncated":"Eoc Pharma \/ Immutep"},{"orgOrder":0,"company":"Alteogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"ALT-P7","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alteogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alteogen \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minerva Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"huMNC2-CAR22","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Minerva Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Minerva Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Minerva Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ASN004","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"China Life Private Equity Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2021","type":"Series C Financing","leadProduct":"GQ1001","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GeneQuantum Healthcare \/ China Life Private Equity Investment","highestDevelopmentStatusID":"6","companyTruncated":"GeneQuantum Healthcare \/ China Life Private Equity Investment"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GMI-1359","moa":"E-selectin","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GMI-1359","moa":"E-selectin","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"GlycoMimetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GMI-1359","moa":"E-selectin","graph1":"Oncology","graph2":"Phase I","graph3":"GlycoMimetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GlycoMimetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GlycoMimetics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Celcuity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Gedatolisib","moa":"PI3K\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pfizer Inc \/ Celcuity","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Celcuity"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"ST316","moa":"Wnt\/beta-catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sapience Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Sapience Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Carisma Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Sesen Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Carisma Therapeutics \/ Sesen Bio","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Sesen Bio"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"OnKure Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ OnKure Therapeutics"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Fulvestrant","moa":"||PI3K-alpha-H1047R","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1611","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Puma Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Alisertib","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Puma Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Takeda Pharmaceutical \/ Puma Biotechnology"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BAY1895344","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"The Institute of Cancer Research \/ Bayer AG"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SY-5609","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"AC0682","moa":"Estrogen-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"AC0682","moa":"Estrogen-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"Lantern Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TTC Oncology \/ Lantern Pharma","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ Lantern Pharma"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University Of Illinois Chicago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TTC Oncology \/ University Of Illinois Chicago","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ University Of Illinois Chicago"},{"orgOrder":0,"company":"TTC Oncology","sponsor":"University Of Illinois Chicago","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TTC Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TTC Oncology \/ University Of Illinois Chicago","highestDevelopmentStatusID":"6","companyTruncated":"TTC Oncology \/ University Of Illinois Chicago"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"TTC Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"TTC-352","moa":"Selective estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lantern Pharma \/ TTC Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ TTC Oncology"},{"orgOrder":0,"company":"Immunolight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methoxsalen","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Immunolight","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Immunolight \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunolight \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Imlunestrant","moa":"||Estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INB03","moa":"TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INB03","moa":"||TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INB03","moa":"||TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"INB03","moa":"TNF-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Ikena Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Pembrolizumab","moa":"||TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pionyr Immunotherapeutics \/ Ikena Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Ikena Oncology"},{"orgOrder":0,"company":"AnHeart Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AB-329","moa":"AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AnHeart Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnHeart Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AnHeart Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InventisBio","sponsor":"GL Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"D-0502","moa":"Estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InventisBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InventisBio \/ GL Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InventisBio \/ GL Ventures"},{"orgOrder":0,"company":"Radius Health","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Vosilasarm","moa":"Selective androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radius Health \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Radius Health \/ Ellipses Pharma"},{"orgOrder":0,"company":"SynDevRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eribulin","moa":"||MetAP2","graph1":"Oncology","graph2":"Phase I","graph3":"SynDevRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SynDevRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SynDevRx \/ Inapplicable"},{"orgOrder":0,"company":"Unum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACTR707","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Unum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Unum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Minerva Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"huMNC2-CAR44","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FHD-909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FHD-909","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"itheranostics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"FAPI-46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"itheranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"itheranostics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"itheranostics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"GORTEC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ GORTEC","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ GORTEC"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-61159","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-61159","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rgenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Silmitasertib","moa":"CK2-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"JWATM214","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NETRIS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Netrin-1","graph1":"Oncology","graph2":"Phase I","graph3":"NETRIS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NETRIS Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NETRIS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eutilex Inc","sponsor":"GenScript ProBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"EU307","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eutilex Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eutilex Inc \/ GenScript ProBio","highestDevelopmentStatusID":"6","companyTruncated":"Eutilex Inc \/ GenScript ProBio"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AFP TCR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sinopharm Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"GFH018","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Sinopharm Capital","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Sinopharm Capital"},{"orgOrder":0,"company":"MAIA Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"THIO-103","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MAIA Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAIA Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MAIA Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"OriCell Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"Ori-C101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"OriCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OriCell Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"OriCell Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Pepper Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lerociclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"G1 Therapeutics, Inc \/ Pepper Bio","highestDevelopmentStatusID":"6","companyTruncated":"G1 Therapeutics, Inc \/ Pepper Bio"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADP\u2011A2AFP","moa":"Alpha-fetoprotein","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Kinnevik AB","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Kinnevik AB","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Kinnevik AB"},{"orgOrder":0,"company":"CohBar","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Private Placement","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CohBar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"CohBar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CohBar \/ Undisclosed"},{"orgOrder":0,"company":"TuHURA Biosciences","sponsor":"CohBar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"IFx-Hu2.0","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TuHURA Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"TuHURA Biosciences \/ CohBar","highestDevelopmentStatusID":"6","companyTruncated":"TuHURA Biosciences \/ CohBar"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD16","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Cancer Research"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lineage Cell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AST-VAC2","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Lineage Cell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Lineage Cell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lineage Cell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Memgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MEM-288","moa":"IFN-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Memgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Memgen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Memgen \/ Inapplicable"},{"orgOrder":0,"company":"Axplora","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2021","type":"Agreement","leadProduct":"Nivolumab","moa":"||Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Axplora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Axplora \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Axplora \/ Exelixis"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Angel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"||CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Angel Pharmaceuticals"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HMBD-002","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hummingbird Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Iconic Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"XB002","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Iconic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iconic Therapeutics \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Iconic Therapeutics \/ Exelixis"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-5552","moa":"||Bi-Steric mTORC1","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CS2009","moa":"PD-1\/VEGF\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI110","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TG6050","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"TG6050","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Osimertinib","moa":"||HER3","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AstraZeneca \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Clinigen Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Clinigen Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clinigen Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clinigen Group \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Acorn Bioventures"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"||MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CTX-8371","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mythic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MYTX-011","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Mythic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mythic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mythic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SystImmune","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"BL-B01D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SystImmune \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"||EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BL-B01D1","moa":"EGFR\/HER3","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Biosion","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CDX-585","moa":"PD-1\/ILT-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celldex Therapeutics \/ Biosion","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Biosion"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gotistobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ITIL-306","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Instil Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Beverly Hills Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Beverly Hills Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Beverly Hills Cancer Center"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MT-8421","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Private Placement","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Stifel","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Stifel"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SEA-TGT","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CART-TnMUC1-01","moa":"||T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"BNT116","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Regeneron Pharmaceuticals \/ BioNTech"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"OrbiMed Asia Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ OrbiMed Asia Partners","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ OrbiMed Asia Partners"},{"orgOrder":0,"company":"Kinnjiu Biopharma","sponsor":"Kinnate Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnjiu Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnjiu Biopharma \/ Kinnate Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Kinnjiu Biopharma \/ Kinnate Biopharma"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-104","moa":"||Liver X receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"ReHeva Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RH324","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ReHeva Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReHeva Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ReHeva Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Suzhou Yasheng Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APG-2449","moa":"FAK\/ALK\/ROS1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Suzhou Yasheng Pharmaceutical"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"JAB-3312","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jacobio Pharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Pharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Biomica","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Inapplicable"},{"orgOrder":0,"company":"Biomica","sponsor":"Shanghai Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Shanghai Healthcare Capital","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Shanghai Healthcare Capital"},{"orgOrder":0,"company":"Biomica","sponsor":"Rambam Health Care Campus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Agreement","leadProduct":"BMC128","moa":"||Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"Biomica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biomica \/ Rambam Health Care Campus","highestDevelopmentStatusID":"6","companyTruncated":"Biomica \/ Rambam Health Care Campus"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"KB707","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6291","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Arrivent","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Arrivent"},{"orgOrder":0,"company":"IMPACT Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Senaparib","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"IMPACT Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IMPACT Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IMPACT Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Furmonertinib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DKY709","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VIC-1911","moa":"||Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"VITRAC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BI 1701963","moa":"Pan-KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"OBI-833","moa":"Globo H","graph1":"Oncology","graph2":"Phase I","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CytoImmune Therapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"CytoImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoImmune Therapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"CytoImmune Therapeutics \/ City of Hope"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iovance Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"OmRx Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OX-4224","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"OmRx Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OmRx Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OmRx Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"PT199","moa":"||CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"M1231","moa":"MUC1-EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck Group"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Helix BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Aveo Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LB-LR1109","moa":"LILRB1","graph1":"Oncology","graph2":"Phase I","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Aveo Oncology","highestDevelopmentStatusID":"6","companyTruncated":"LG Chem \/ Aveo Oncology"},{"orgOrder":0,"company":"BioNTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"YL202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioNTech \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Dendritic Cell Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diakonos Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Inapplicable"},{"orgOrder":0,"company":"T-Cure Bioscience","sponsor":"Immunotech Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"HERV-E TCR Transduced CD8+\/CD34+ Enriched T Cell","moa":"HERV-E","graph1":"Oncology","graph2":"Phase I","graph3":"T-Cure Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"T-Cure Bioscience \/ Immunotech Biopharm","highestDevelopmentStatusID":"6","companyTruncated":"T-Cure Bioscience \/ Immunotech Biopharm"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARO-HIF2","moa":"HIF-2-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DS-6000","moa":"CDH6 IgG1","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sarah Cannon Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DS-6000","moa":"CDH6 IgG1","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Sarah Cannon Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Sarah Cannon Research Institute"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medicenna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDNA11","moa":"||IL-2-beta-receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medicenna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medicenna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medicenna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HC-5404","moa":"Endoplasmic reticulum stress","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HC-5404","moa":"Endoplasmic reticulum stress","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Labcorp Drug Development"},{"orgOrder":0,"company":"HiberCell","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Merck & Co"},{"orgOrder":0,"company":"Exelixis","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Arcus Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Arcus Biosciences"},{"orgOrder":0,"company":"Exelixis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Sotio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Merck & Co"},{"orgOrder":0,"company":"Sotio","sponsor":"PPF Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sotio \/ PPF Group","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ PPF Group"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mitazalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"VIB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ VIB","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ VIB"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase I","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Lytix Biopharma \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Checkpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Cosibelimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Samsung Biologics \/ Checkpoint Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Biologics \/ Checkpoint Therapeutics"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HB-200","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hookipa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HB-200","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Hookipa Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hookipa Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hookipa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Enfortumab Vedotin","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Exelixis"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IK-175","moa":"||AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Merck Group"},{"orgOrder":0,"company":"Immutep","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Immutep \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Merck Group"},{"orgOrder":0,"company":"Aprea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"APR-1051","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aprea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aprea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aprea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Termination","leadProduct":"Plamotamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ALLO-316","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ONC206","moa":"D2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncoceutics Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoceutics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TYRA-200","moa":"FGFR-1\/FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KIN-3248","moa":"FGFR-2\/FGFR-3","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Lucid Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Lucid Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Lucid Capital Markets"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Lucid Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Lucid Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Lucid Capital Markets"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Lucid Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Lucid Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Lucid Capital Markets"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Mayo Clinic"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Elevation Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Elevation Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elevation Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevation Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Third Arc Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"ARC101","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"Third Arc Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Third Arc Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Third Arc Bio \/ Inapplicable"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mythic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MYTX-011","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Mythic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mythic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mythic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase I","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Iterion Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Netherlands Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Netherlands Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Netherlands Cancer Institute"},{"orgOrder":0,"company":"National Health Research Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DBPR115","moa":"Cancer cell membrane protein-phosphatidyl serine","graph1":"Oncology","graph2":"Phase I","graph3":"National Health Research Institutes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Health Research Institutes \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Health Research Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tizona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Efineptakin Alpha","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Genexine \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"Oncoinvent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Oncoinvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Oncoinvent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncoinvent \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||mTORC1","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||mTORC1","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Taiga Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TBX-3400","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Taiga Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiga Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Taiga Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Invios","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invios \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Austrian Research Promotion Agency"},{"orgOrder":0,"company":"Celyad","sponsor":"Fortress Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Private Placement","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Fortress Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Fortress Investment Group"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-101","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Merck & Co"},{"orgOrder":0,"company":"LipoMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Promitil","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovative Cellular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GCC19CART","moa":"Guanylyl cyclase C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovative Cellular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovative Cellular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovative Cellular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bionomics","sponsor":"Carina Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"BNC101","moa":"LGR5","graph1":"Oncology","graph2":"Phase I","graph3":"Bionomics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Bionomics \/ Carina Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Bionomics \/ Carina Biotech"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"PF-08046052","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lava Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Apros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APR003","moa":"Toll-like-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Apros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Apros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wellmarker Bio","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"WM-S1-030","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Wellmarker Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Wellmarker Bio \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"Wellmarker Bio \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ DCVC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ DCVC Bio"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Sands Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series D Financing","leadProduct":"Irinotecan","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Sands Capital","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Sands Capital"},{"orgOrder":0,"company":"Rgenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RGX-202","moa":"SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenix \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Series B Financing","leadProduct":"Carboplatin","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ MPM BioImpact","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ MPM BioImpact"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Angion Biomedica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Angion Biomedica","highestDevelopmentStatusID":"6","companyTruncated":"Elicio Therapeutics \/ Angion Biomedica"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"TIDAL-01","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ BofA Securities"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ BofA Securities"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TIDAL-01","moa":"T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Turnstone Biologics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"TIDAL-01","moa":"||T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Turnstone Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turnstone Biologics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Turnstone Biologics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Trigr","sponsor":"Elpiscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Asciminib","moa":"DLL4-Notch1","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trigr \/ Elpiscience","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Elpiscience"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LB-100","moa":"PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NKT3447","moa":"CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Signet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"sigx1094","moa":"FAK\/YAP","graph1":"Oncology","graph2":"Phase I","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Signet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Signet \/ Inapplicable"},{"orgOrder":0,"company":"BrainChild Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BCB-276","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"BrainChild Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"BrainChild Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BrainChild Bio \/ Inapplicable"},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"BrainChild Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SC-CAR4BRAIN","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Seattle Children\u2019s Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seattle Children\u2019s Research Institute \/ BrainChild Bio","highestDevelopmentStatusID":"6","companyTruncated":"Seattle Children\u2019s Research Institute \/ BrainChild Bio"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paxalisib","moa":"||PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Paxalisib","moa":"||PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"124-I Omburtamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Luca Szalontay","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Luca Szalontay","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Luca Szalontay"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"MPM Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"VK-2019","moa":"EBNA-1","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullinan Therapeutics \/ MPM Capital","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ MPM Capital"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRG01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"CFT8919","moa":"EGFR L858R","graph1":"Oncology","graph2":"Phase I","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"C4 Therapeutics \/ Betta Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"C4 Therapeutics \/ Betta Pharmaceuticals"},{"orgOrder":0,"company":"Biotheus","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"HS-20117","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biotheus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biotheus \/ Hansoh Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Biotheus \/ Hansoh Pharma"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Nextech"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CX-904","moa":"EGFR-CD3 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Carotuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kairos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NextPoint","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series B Financing","leadProduct":"NPX267","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextPoint \/ Catalio Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint \/ Catalio Capital Management"},{"orgOrder":0,"company":"NextPoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"NPX267","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextPoint \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint \/ Inapplicable"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ AstraZeneca"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"BBP-398","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"LianBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"LianBio \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"LianBio \/ AstraZeneca"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DK210","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"IDE161","moa":"||PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDE161","moa":"||PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"CX-2051","moa":"EpCAM","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"CX-2051","moa":"EpCAM","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"WP1066","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olema Oncology \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Olema Oncology \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Paradigm BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olema Oncology \/ Paradigm BioCapital","highestDevelopmentStatusID":"6","companyTruncated":"Olema Oncology \/ Paradigm BioCapital"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AC699","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"Evexta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rupitasertib","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Evexta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evexta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evexta Bio \/ Inapplicable"},{"orgOrder":0,"company":"Diaccurate","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DIACC3010","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diaccurate","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diaccurate \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diaccurate \/ Inapplicable"},{"orgOrder":0,"company":"Olema Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Palazestrant","moa":"||Complete estrogen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Olema Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olema Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Olema Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"225-Ac Satoreotide Tetraxetan","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"225-Ac Satoreotide Tetraxetan","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"BBI-355","moa":"||CHK-1","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Taiho Oncology"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORIC-114","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMF-500","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW191","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI 905711","moa":"TRAILR2","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"LaNova Medicines","sponsor":"Turning Point Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"LM-302","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"LaNova Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"LaNova Medicines \/ Turning Point Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"LaNova Medicines \/ Turning Point Therapeutics"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arbele","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"CDH17","graph1":"Oncology","graph2":"Phase I","graph3":"Arbele","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Arbele \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbele \/ Inapplicable"},{"orgOrder":0,"company":"Arbele","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"CDH17","graph1":"Oncology","graph2":"Phase I","graph3":"Arbele","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Arbele \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbele \/ Inapplicable"},{"orgOrder":0,"company":"Elion Oncology","sponsor":"Processa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Elion Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elion Oncology \/ Processa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Elion Oncology \/ Processa Pharmaceuticals"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inspirna","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan HCl Trihydrate","moa":"||SLC6A8\/CKB pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Inspirna","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inspirna \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inspirna \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DOTA","moa":"||GD2","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Celleron","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Emactuzumab","moa":"CSF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Celleron","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Celleron"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Diakonos Oncology","sponsor":"Restem Group Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"DOC1021","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Diakonos Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diakonos Oncology \/ Restem Group Inc","highestDevelopmentStatusID":"6","companyTruncated":"Diakonos Oncology \/ Restem Group Inc"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CVGBM","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ITI-1001","moa":"pp65","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunomic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ITI-1001","moa":"pp65","graph1":"Oncology","graph2":"Phase I","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Immunomic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunomic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Midatech Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Midatech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CHM 1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Chimeric Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chimeric Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"WuXi Advanced Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"CHM 1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Chimeric Therapeutics \/ WuXi Advanced Therapies","highestDevelopmentStatusID":"6","companyTruncated":"Chimeric Therapeutics \/ WuXi Advanced Therapies"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Helmholtz Zentrum M\u00fcnchen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Isotope Technologies Munich \/ Helmholtz Zentrum M\u00fcnchen","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ Helmholtz Zentrum M\u00fcnchen"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"University Hospital Muenster","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ITM-31","moa":"CA XII","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Isotope Technologies Munich \/ University Hospital Muenster","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ University Hospital Muenster"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"GM-CSF","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NU-0129","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Calidi Biotherapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"WPD Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IAG, Image Analysis Group","sponsor":"CNS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2020","type":"Partnership","leadProduct":"Berubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"IAG, Image Analysis Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IAG, Image Analysis Group \/ CNS Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"IAG, Image Analysis Group \/ CNS Pharmaceuticals"},{"orgOrder":0,"company":"University of Florida","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RNA-LNP Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"University of Florida","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Florida \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"University of Florida \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Financing","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ White Lion Capital","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ White Lion Capital"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ERAS-801","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ERAS-801","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase I","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DSP-0390","moa":"EBP","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"GCAR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"AZD1390","moa":"ATM","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ GCAR","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ GCAR"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BDTX-1535","moa":"Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"BDTX-1535","moa":"||Allosteric EGFR selective","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"IQ-AI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gallium Maltolate","moa":"RRM2","graph1":"Oncology","graph2":"Phase I","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medical College of Wisconsin \/ IQ-AI","highestDevelopmentStatusID":"6","companyTruncated":"Medical College of Wisconsin \/ IQ-AI"},{"orgOrder":0,"company":"BullFrog","sponsor":"Sage Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"BF-222","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BullFrog","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BullFrog \/ Sage Group","highestDevelopmentStatusID":"6","companyTruncated":"BullFrog \/ Sage Group"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"MB-101","moa":"||IL-13-alpha-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MB-101","moa":"IL-13-alpha-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ City of Hope"},{"orgOrder":0,"company":"OX2 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"hP1A8","moa":"Immune checkpoint","graph1":"Oncology","graph2":"Phase I","graph3":"OX2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OX2 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OX2 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanopharmaceutics","sponsor":"Northwestern University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"3-aminopyridine-2-carboxaldehyde thiosemicarbazone","moa":"||RNR","graph1":"Oncology","graph2":"Phase I","graph3":"Nanopharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanopharmaceutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"Nanopharmaceutics \/ Northwestern University"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"NNV1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwestern University \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Northwestern University \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"CAN-3110","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Batavia Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Batavia Bioscience \/ Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Batavia Bioscience \/ Candel Therapeutics"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CAN-3110","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CAN-3110","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"CAN-3110","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Candel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Saposin C-dioleoylphosphatidylserine","moa":"Spingomyelinase catalysis","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Samus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icapamespib","moa":"Epichaperome","graph1":"Oncology","graph2":"Phase I","graph3":"Samus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Samus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MB-108","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"PeriphaGen","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Acquisition","leadProduct":"rQNestin34.5","moa":"ICP34.5","graph1":"Oncology","graph2":"Phase I","graph3":"PeriphaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeriphaGen \/ Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"PeriphaGen \/ Candel Therapeutics"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CT011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Galapagos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Nivolumab","moa":"||MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Galapagos","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Galapagos"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Uzatresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theragnostics","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"ATD-001","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theragnostics \/ Ariceum Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Theragnostics \/ Ariceum Therapeutics"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-175","moa":"||AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"NEC Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ NEC Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ NEC Corporation"},{"orgOrder":0,"company":"Merus","sponsor":"Chiltern International Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR\/LGR5","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merus \/ Chiltern International Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Chiltern International Ltd"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TSC-203-A0201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"VelosBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Zilovertamab","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Matrix Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/ Matrix Capital Management"},{"orgOrder":0,"company":"VelosBio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Zilovertamab","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/ Merck & Co"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"PRT2527","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Trillium Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Ontorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Trillium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trillium Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Trillium Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GenFleet Therapeutics \/ Sellas Life Sciences Group","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Sellas Life Sciences Group"},{"orgOrder":0,"company":"Onward Therapeutics","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"OT-A201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Onward Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onward Therapeutics \/ Biomunex Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Onward Therapeutics \/ Biomunex Pharmaceutical"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PRT1419","moa":"MCL1","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATG-017","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HMPL-306","moa":"IDH-1","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BTX-1188","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APG-5918","moa":"EED","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"APG-5918","moa":"EED","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MDG1021","moa":"Antigen HA-1","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Orca Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Orca-Q","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Orca Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orca Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orca Bio \/ Inapplicable"},{"orgOrder":0,"company":"Trillium Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Maplirpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Trillium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trillium Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Trillium Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Cellectis","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Servier"},{"orgOrder":0,"company":"Cellectis","sponsor":"Servier Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"UCART19","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Servier Canada","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Servier Canada"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"LAVA-051","moa":"CD1d","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lava Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"ABBV-525","moa":"MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Lupin Ltd \/ AbbVie Inc"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT825","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Iksuda Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"IKS014","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Iksuda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iksuda Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iksuda Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Nuvalent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NVL-330","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvalent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvalent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvalent \/ Inapplicable"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"IAM1363","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iambic Therapeutics \/ Mubadala Capital","highestDevelopmentStatusID":"6","companyTruncated":"Iambic Therapeutics \/ Mubadala Capital"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CT-0508","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Carisma Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"EirGenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"EGFR2","graph1":"Oncology","graph2":"Phase I","graph3":"EirGenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EirGenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EirGenix \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu RAD202","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"Bliss Bio","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Collaboration","leadProduct":"BB-1701","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Bliss Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bliss Bio \/ Eisai","highestDevelopmentStatusID":"6","companyTruncated":"Bliss Bio \/ Eisai"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CT-0525","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CT-0525","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Public Offering","leadProduct":"SBT6050","moa":"Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"NextPoint","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"NPX887","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NextPoint","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextPoint \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NextPoint \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lisaftoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Pionyr Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Pionyr Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Pionyr Immunotherapeutics"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ TD Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ TD Cowen"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||CD30","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Merck & Co"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CUE-101","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Lopinavir","moa":"||HIV-1 protease","graph1":"Oncology","graph2":"Phase I","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"Dar\u00e9 Bioscience \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Dar\u00e9 Bioscience \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"RGT-419B","moa":"CDK4","graph1":"Oncology","graph2":"Phase I","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regor Therapeutics \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Regor Therapeutics \/ Genentech"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BTX-9341","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BTX-9341","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGT-419B","moa":"CDK4","graph1":"Oncology","graph2":"Phase I","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Ensem Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BG-68501","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Ensem Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ Ensem Therapeutics"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"LX-101","moa":"||IGF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lirum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lirum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lirum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IDRx","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":1.1499999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.1499999999999999,"dosageForm":"Oral Tablet","sponsorNew":"IDRx \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ GSK"},{"orgOrder":0,"company":"IDRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IDRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ Inapplicable"},{"orgOrder":0,"company":"IDRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IDRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ Inapplicable"},{"orgOrder":0,"company":"IDRx","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"IDRX-42","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"IDRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IDRx \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"IDRx \/ RA Capital Management"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Merck Group"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBO-8520","moa":"GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Cormorant Asset Management"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Adagrasib","moa":"||Farnesyl transferase","graph1":"Oncology","graph2":"Phase I","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kura Oncology \/ Mirati Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Kura Oncology \/ Mirati Therapeutics"},{"orgOrder":0,"company":"GenFleet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GFH925","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"GenFleet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GenFleet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GenFleet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||KRAS G12C","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RMC-9805","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"QTX3544","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Quanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Oncology Therapeutics","sponsor":"Helix Acquisition Corp. II","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Oncology Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Oncology Therapeutics \/ Helix Acquisition Corp. II","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Oncology Therapeutics \/ Helix Acquisition Corp. II"},{"orgOrder":0,"company":"BridgeBio Oncology Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BBO-8520","moa":"||GTP","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Oncology Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Oncology Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Oncology Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alterome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ALTA3263","moa":"KRAS ON\/OFF","graph1":"Oncology","graph2":"Phase I","graph3":"Alterome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alterome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alterome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Unesbulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Unesbulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Plus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Plus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Plus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Plus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Cantor Fitzgerald","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"University of Kansas Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ University of Kansas Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ University of Kansas Cancer Center"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Precigen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Precigen","highestDevelopmentStatusID":"6","companyTruncated":"Alaunos Therapeutics \/ Precigen"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioheng Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Anti-Cd19 Ucar-T","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART22","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Halix BV","sponsor":"NovalGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halix BV \/ NovalGen","highestDevelopmentStatusID":"6","companyTruncated":"Halix BV \/ NovalGen"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVA-001","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avalon GloboCare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CNTY-101","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNTY-101","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Century Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CNTY-101","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Century Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Century Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Century Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"AC0676","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"AC0676","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zandelisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NX-2127","moa":"Mpro","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Starton Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Starton Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Starton Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Starton Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Expert Systems","sponsor":"Lomond Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonitoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Expert Systems","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Expert Systems \/ Lomond Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Expert Systems \/ Lomond Therapeutics"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Expert Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eiletoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Expert Systems","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Expert Systems"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Commodore Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Commodore Capital","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Commodore Capital"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Imara"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"TERN-701","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Terns Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Xspray Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase I","graph3":"Xspray Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xspray Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xspray Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Fairmount Funds Management LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Fairmount Funds Management LLC","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Fairmount Funds Management LLC"},{"orgOrder":0,"company":"Enliven Therapeutics","sponsor":"Imara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Merger","leadProduct":"ELVN-001","moa":"BCR-ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Enliven Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Enliven Therapeutics \/ Imara","highestDevelopmentStatusID":"6","companyTruncated":"Enliven Therapeutics \/ Imara"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CLN-049","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CLN-049","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MultiTAA-Specific T Cell","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SC-DARIC33","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"2Seventy Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy Bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Inapplicable"},{"orgOrder":0,"company":"IN8bio","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"INB-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IN8bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IN8bio \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"IN8bio \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IO-202","moa":"LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Oceanpine Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ Oceanpine Capital","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Oceanpine Capital"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Amplitude Healthcare Acquisition Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Merger","leadProduct":"Briquilimab","moa":"||CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Amplitude Healthcare Acquisition Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Amplitude Healthcare Acquisition Corporation"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"||CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vibecotamab","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Vibecotamab","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"NKX101","moa":"NKG2DL","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-02","moa":"NKG2D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UCART123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"UCART123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"UCART123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Jefferies"},{"orgOrder":0,"company":"Cellectis","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"UCART123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectis \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Jefferies"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Filgrastim","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cytarabine HCl","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Lava Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LAVA-1266","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Lava Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lava Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lava Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PRGN-3006","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PRGN-3006","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-253","moa":"||MDM2","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-101","moa":"HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KT-253","moa":"MDM2","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"LYT-200","moa":"Galectin-9","graph1":"Oncology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"LYT-200","moa":"Galectin-9","graph1":"Oncology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PureTech Health \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-101","moa":"HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSC-101","moa":"HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TSC-101","moa":"HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"TSC-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Fludarabine","moa":"||HA-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ K2 HealthVentures","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ K2 HealthVentures"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Lynx1 Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"TSC-100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TScan Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"TScan Therapeutics \/ Lynx1 Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"TScan Therapeutics \/ Lynx1 Capital Management"},{"orgOrder":0,"company":"Celularity","sponsor":"GX Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ GX Acquisition Corp","highestDevelopmentStatusID":"6","companyTruncated":"Celularity \/ GX Acquisition Corp"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Celularity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celularity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celularity \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"DVX201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coeptis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coeptis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UniCAR-T-CD123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Inapplicable"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UniCAR-T-CD123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Inapplicable"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"UniCAR-T-CD123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Undisclosed"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"BP1002","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BP1002","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Midcap Financial Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Azacitidine","moa":"||CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Midcap Financial Trust","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Midcap Financial Trust"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Deverra Therapeutics","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"DVX201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Deverra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deverra Therapeutics \/ Coeptis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Deverra Therapeutics \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"Mana Therapeutics","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"MANA-312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mana Therapeutics \/ Cobro Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Mana Therapeutics \/ Cobro Ventures"},{"orgOrder":0,"company":"Iterion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tegavivint","moa":"TBL1","graph1":"Oncology","graph2":"Phase I","graph3":"Iterion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iterion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Iterion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-500","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMF-500","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ J.P. Morgan"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ J.P. Morgan"},{"orgOrder":0,"company":"Effector Therapeutics","sponsor":"Northwestern University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Tomivosertib","moa":"MAPK-1\/MAPK-2","graph1":"Oncology","graph2":"Phase I","graph3":"Effector Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Effector Therapeutics \/ Northwestern University","highestDevelopmentStatusID":"6","companyTruncated":"Effector Therapeutics \/ Northwestern University"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alrizomadlin","moa":"||MDM2-p53","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"Roivant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"H3B-8800","moa":"pre-mRNA","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eisai \/ Roivant Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Roivant Sciences"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RVU120","moa":"CDK8","graph1":"Oncology","graph2":"Phase I","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"FHD-286","moa":"Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZN-D5","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cleave Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cleave Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imago BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bomedemstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Imago BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Imago BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imago BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aptose Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Luxeptinib","moa":"FLT3\/BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Aptose Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptose Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aptose Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MaaT033","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"MaaT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaaT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Remedy Plan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RPT1G","moa":"NAMPT","graph1":"Oncology","graph2":"Phase I","graph3":"Remedy Plan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Remedy Plan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Remedy Plan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"MSD Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"BTX-A51","moa":"CK1-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioTheryX \/ MSD Partners","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ MSD Partners"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"GeneFab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ GeneFab","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ GeneFab"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Celadon Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Celadon Partners","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Celadon Partners"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Celadon Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Celadon Partners","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Celadon Partners"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Dynamics Special Purpose Corp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Dynamics Special Purpose Corp","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Dynamics Special Purpose Corp"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B financing","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Leaps by Bayer"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Funding","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Senti Biosciences \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ National Cancer Institute"},{"orgOrder":0,"company":"Lynk Pharmaceuticals","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"LNK01002","moa":"Triple kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Lynk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lynk Pharmaceuticals \/ Lilly Asia Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Lynk Pharmaceuticals \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Vevoctadekin","moa":"IL-18 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Simcha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Simcha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Cirtuvivint","moa":"CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biosplice \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Mateon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Combretastatin A1 Diphosphate","moa":"Tubulin polymerisation","graph1":"Oncology","graph2":"Phase I","graph3":"Mateon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mateon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mateon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eiletoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qurient","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Adrixetinib","moa":"||AXL\/Mer\/CSF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Qurient","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qurient \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Qurient \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MP0533","moa":"CD33\/CD123\/CD70","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Partners \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Partners \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"MGD024","moa":"CD3\/123","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Gilead Sciences"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"ORM-6151","moa":"CD33\/GSPT1","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ORM-6151","moa":"CD33\/GSPT1","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclacel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I","graph3":"Cyclacel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclacel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclacel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM28","moa":"CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AFM28","moa":"CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM28","moa":"||CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM28","moa":"||CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AFM28","moa":"CD16A\/123","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affimed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Inapplicable"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVC-101","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AvenCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immune-Onc Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tinostamustine","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Inapplicable"},{"orgOrder":0,"company":"Miragen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cobomarsen","moa":"miR-155","graph1":"Oncology","graph2":"Phase I","graph3":"Miragen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Miragen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Miragen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BST02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"BioSyngen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BST02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioSyngen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioSyngen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioSyngen \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"exoASO-STAT6","moa":"STAT6","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Tvardi Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"EXACT Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"EXACT Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EXACT Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"EXACT Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Afamitresgene Autoleucel","moa":"5-HT2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ImPact Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"Lipid peroxidation","graph1":"Oncology","graph2":"Phase I","graph3":"ImPact Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImPact Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImPact Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Lyvgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"LVGN6051","moa":"||CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Lyvgen","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Lyvgen"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Maplirpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SLS009","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BP1002","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BP1002","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Icatolimab","moa":"||BTLA","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Junshi Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"GRC 54276","moa":"||HPK1","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ichnos Sciences \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sciences \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Hutchison China MediTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amdizalisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchison China MediTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchison China MediTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchison China MediTech \/ Inapplicable"},{"orgOrder":0,"company":"OncoTartis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"OT-82","moa":"NAMPT","graph1":"Oncology","graph2":"Phase I","graph3":"OncoTartis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"OncoTartis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoTartis \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-413","moa":"IRAKIMiD","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CB-010","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Jefferies"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Jefferies"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ BofA Securities"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Farallon Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Farallon Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Farallon Capital Management"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD3\/20","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD3\/20","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Imvotamab","moa":"CD3\/20","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"PRT2527","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"PRT2527","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CTX110","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"C-CAR066","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"Immunome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IM-1021","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immunome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Immunome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunome \/ Inapplicable"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kuur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lysarc","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Lysarc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lysarc \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"Lysarc \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FT516","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FT516","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CLN-978","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TNB-486","moa":"CD3\/19","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Ancora Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TNB-486","moa":"CD3\/19","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Ancora Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Ancora Biotech"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT819","moa":"||CAR19 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FT819","moa":"CAR19 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juventas Cell Therapy","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Inaticabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Juventas Cell Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Juventas Cell Therapy \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Juventas Cell Therapy \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Acepodia","sponsor":"Digital Mobile Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2023","type":"Series D Financing","leadProduct":"ACE1831","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acepodia \/ Digital Mobile Venture","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Digital Mobile Venture"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"NeoImmuneTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efineptakin Alpha","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NeoImmuneTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"NeoImmuneTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoImmuneTech \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"CS5001","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"C-CAR039","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nordic Nanovector \/ Inapplicable"},{"orgOrder":0,"company":"TeneoTwo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"TNB-486","moa":"CD3\/19","graph1":"Oncology","graph2":"Phase I","graph3":"TeneoTwo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TeneoTwo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"TeneoTwo \/ AstraZeneca"},{"orgOrder":0,"company":"TeneoTwo","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"TNB-486","moa":"CD3\/19","graph1":"Oncology","graph2":"Phase I","graph3":"TeneoTwo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TeneoTwo \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"TeneoTwo \/ AstraZeneca"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"Double Point Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series C Financing","leadProduct":"Rapamycin","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Umoja Biopharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ Double Point Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Umoja Biopharma \/ Double Point Ventures"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"STK-009","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"VelosBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Zilovertamab","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"VelosBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VelosBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VelosBio \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TG-1701","moa":"||BTK","graph1":"Oncology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"SIRPant Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SIRPant Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"SIRPant Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SIRPant Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CB-010","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CellReady","sponsor":"Marker Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"CellReady","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CellReady \/ Marker Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"CellReady \/ Marker Therapeutics"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"5 Fluorouracil","moa":"||DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ BofA Securities"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nkarta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"TRPH-222","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triphase Accelerator \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Triphase Accelerator \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"TRPH-222","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triphase Accelerator \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Triphase Accelerator \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"resTORbio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Merger","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ resTORbio","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ resTORbio"},{"orgOrder":0,"company":"SkylineDx","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"BI-1206","moa":"||CD32B","graph1":"Oncology","graph2":"Phase I","graph3":"SkylineDx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SkylineDx \/ BioInvent","highestDevelopmentStatusID":"6","companyTruncated":"SkylineDx \/ BioInvent"},{"orgOrder":0,"company":"Tessa Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TT11X","moa":"CD30","graph1":"Oncology","graph2":"Phase I","graph3":"Tessa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tessa Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Tessa Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Biotechnology Value Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"KT-413","moa":"IRAKIMiD","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Biotechnology Value Fund","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Biotechnology Value Fund"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"AstraZeneca-CICC Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"C-CAR039","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ AstraZeneca-CICC Fund","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ AstraZeneca-CICC Fund"},{"orgOrder":0,"company":"Cellular Biomedicine Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"C-CAR039","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"Cellular Biomedicine Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellular Biomedicine Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellular Biomedicine Group \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DOTA","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Deerfield Management","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Deerfield Management"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Morgan Stanley"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sana Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"ImmPACT Bio","sponsor":"Venbio Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"ImmPACT Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ImmPACT Bio \/ Venbio Partners","highestDevelopmentStatusID":"6","companyTruncated":"ImmPACT Bio \/ Venbio Partners"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mesutoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"TG Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TG-1701","moa":"||BTK","graph1":"Oncology","graph2":"Phase I","graph3":"TG Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TG Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TG Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XL114","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBCAR19B","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBCAR19B","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBCAR19B","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Decoy Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"Deuterium Stabilized(S)-Avadomide","moa":"Cereblon","graph1":"Oncology","graph2":"Phase I","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Decoy Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Salarius Pharmaceuticals \/ Decoy Therapeutics"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX130","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SciTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Storm Lake Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Fenretinide","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Storm Lake Capital","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Storm Lake Capital"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LB1901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB1901","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vittoria Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"IL-2 induced T-cell kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"IL-2 induced T-cell kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"IL-2 induced T-cell kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Soquelitinib","moa":"IL-2 induced T-cell kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GC Cell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AB-205","moa":"||CD5","graph1":"Oncology","graph2":"Phase I","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Cell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GC Cell \/ Inapplicable"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vittoria Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Valley Forge Investment Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Valley Forge Investment Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Private Placement","leadProduct":"VIPER-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Valley Forge Investment Corporation"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"exoIL-12","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Codiak BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Codiak BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ontorpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-333","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KT-333","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Moleculin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WP1220","moa":"p-STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Moleculin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Moleculin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Moleculin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CT125A","moa":"CD5","graph1":"Oncology","graph2":"Phase I","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IASO Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IASO Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-333","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KT-333","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kymera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kymera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vyriad","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Vyriad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vyriad \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Vyriad \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Interius BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Interius BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RO7617991","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pasithea Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Anbogen Therapeutics","sponsor":"KGI Venture Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"ABT-301","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Anbogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anbogen Therapeutics \/ KGI Venture Capital","highestDevelopmentStatusID":"6","companyTruncated":"Anbogen Therapeutics \/ KGI Venture Capital"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Omburtamab-DTPA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Omburtamab-DTPA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Ipilimumab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Mayo Clinic \/ Sorrento Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Mayo Clinic \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"CV8102","moa":"Toll-like-7\/Toll-like-8\/RIG-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"CV8102","moa":"Toll-like-7\/Toll-like-8\/RIG-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"CureVac","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"CV8102","moa":"Toll-like-7\/Toll-like-8\/RIG-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"CureVac \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CureVac \/ Inapplicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Biotheus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"Igrelimogene Litadenorepvec","moa":"TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ Biotheus","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Biotheus"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Avelumab","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Igrelimogene Litadenorepvec","moa":"TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/ Inapplicable"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Indaco Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Financing","leadProduct":"Cyclophosphamide","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Indaco Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Indaco Venture Partners"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Texcell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Texcell","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Texcell"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oncorus","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"ONCR-177","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Oncorus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Oncorus \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Oncorus \/ Merck & Co"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Phio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"PH-762","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Phio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Phio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL845","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Invios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invios \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||CD4 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Genocea","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Fludarabine","moa":"||CD4 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genocea \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genocea \/ Inapplicable"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seres Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seres Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spirita Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"E6201","moa":"||MEK1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Spirita Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spirita Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spirita Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Merger","leadProduct":"SGN-BB228","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Palvella Therapeutics \/ Pieris Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Palvella Therapeutics \/ Pieris Pharmaceuticals"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Ennovation Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Ennovation Ventures","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Ennovation Ventures"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"||Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Texas Heart Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ Texas Heart Institute","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Texas Heart Institute"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Erasca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Naporafenib","moa":"Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Erasca","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Erasca"},{"orgOrder":0,"company":"Sairopa","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"ADU-1604","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Sairopa","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Sairopa \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Sairopa \/ Exelixis"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eganelisib","moa":"||PI3K gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinity Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Infinity Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"REC-2282","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ZW171","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA2271","moa":"MSLN","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATA2271","moa":"MSLN","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATA2271","moa":"MSLN","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Termination","leadProduct":"ATA2271","moa":"||MSLN","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrapleural Injection","sponsorNew":"Atara Biotherapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1017","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HMPL-506","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Suzhou Puhe Biopharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"BAY 3713372","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Suzhou Puhe Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Suzhou Puhe Biopharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Puhe Biopharma \/ Bayer AG"},{"orgOrder":0,"company":"CSPC Zhongqi Pharmaceutical Technology","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SYH2039","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Zhongqi Pharmaceutical Technology","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Undisclosed","sponsorNew":"CSPC Zhongqi Pharmaceutical Technology \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Zhongqi Pharmaceutical Technology \/ BeiGene"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IDE397","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"FT576","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CAR-BCMA T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UCARTCS1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UCARTCS1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ISB 2001","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ISB 2001","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-647","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ALLO-715","moa":"||B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Allogene Therapeutics \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"TNB-383B","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TNB-383B","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amgen Inc \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ AbbVie Inc"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Nektar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nektar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nektar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CYAD-211","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celyad \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CT071","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"IASO Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ IASO Bio","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ IASO Bio"},{"orgOrder":0,"company":"Precision Autoimmune Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Financing","leadProduct":"CID-103","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Precision Autoimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision Autoimmune Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Precision Autoimmune Therapeutics \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Pregene","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"PRG1801","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pregene \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Daratumumab","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Gadeta","sponsor":"Clade Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"GDT002","moa":"Gamma-delta-T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gadeta \/ Clade Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ Clade Therapeutics"},{"orgOrder":0,"company":"Gadeta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GDT002","moa":"Gamma-delta-T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Gadeta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gadeta \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gadeta \/ Inapplicable"},{"orgOrder":0,"company":"Anaveon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ANV419","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Anaveon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anaveon \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anaveon \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CID-103","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CASI Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Beijing Tianshi Tongda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"CID-103","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CASI Pharmaceuticals \/ Beijing Tianshi Tongda Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"CASI Pharmaceuticals \/ Beijing Tianshi Tongda Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"GC012F","moa":"BCMA\/CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Myeloma Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"NTX-1088","moa":"CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nectin Therapeutics \/ Myeloma Investment Fund","highestDevelopmentStatusID":"6","companyTruncated":"Nectin Therapeutics \/ Myeloma Investment Fund"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Carfilzomib","moa":"||SIRP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MT-0169","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MT-0169","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"TAK-169","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EsoBiotec \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biomea Fusion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMF-219","moa":"Menin","graph1":"Oncology","graph2":"Phase I","graph3":"Biomea Fusion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biomea Fusion \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biomea Fusion \/ Inapplicable"},{"orgOrder":0,"company":"K36 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KTX-1001","moa":"Methyltransferase","graph1":"Oncology","graph2":"Phase I","graph3":"K36 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"K36 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"K36 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"K36 Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"KTX-1001","moa":"Methyltransferase","graph1":"Oncology","graph2":"Phase I","graph3":"K36 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"K36 Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"K36 Therapeutics \/ Nextech"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BB21217","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"2Seventy Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"2Seventy Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"2Seventy Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Varegacestat","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ayala Pharmaceuticals \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Pharmaceuticals \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PF-06863135","moa":"CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"QXL138AM","moa":"CD138","graph1":"Oncology","graph2":"Phase I","graph3":"Nammi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nammi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nammi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"QXL138AM","moa":"CD138","graph1":"Oncology","graph2":"Phase I","graph3":"Nammi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nammi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nammi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Kite Pharma"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"CB-011","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Hadassah Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"HBI0101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immix Biopharma \/ Hadassah Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Immix Biopharma \/ Hadassah Medical Center"},{"orgOrder":0,"company":"Nammi Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"QXL138AM","moa":"CD138","graph1":"Oncology","graph2":"Phase I","graph3":"Nammi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nammi Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nammi Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"oNKord","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycostem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Glycostem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"MEDI2228","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Arcellx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ACLX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcellx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arcellx \/ Inapplicable"},{"orgOrder":0,"company":"Arcellx","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Expanded Collaboration","leadProduct":"ACLX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Arcellx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcellx \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Arcellx \/ Kite Pharma"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Uzatresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CG Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Cretostimogene Grenadenorepvec","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"CG Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"CG Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CG Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Briquilimab","moa":"CD117","graph1":"Oncology","graph2":"Phase I","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PRGN-3006","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Iadademstat","moa":"||LSD1","graph1":"Oncology","graph2":"Phase I","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R289","moa":"IRAK1\/IRAK4","graph1":"Oncology","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MNV-201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Minovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Minovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OPN-2853","moa":"||BRD4-selective protein","graph1":"Oncology","graph2":"Phase I","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Opna Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Opna Bio \/ Inapplicable"},{"orgOrder":0,"company":"ProBioGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"ProBioGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProBioGen \/ Inapplicable"},{"orgOrder":0,"company":"Antennova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATG-031","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Antennova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Antennova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antennova \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AB011","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Niraparib","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATRC-101","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BAT7104","moa":"PD-1\/PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IBI322","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Osemitamab","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI 770371","moa":"||SIRP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"KD033","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"FameWave","sponsor":"Kitov Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"CM-24","moa":"||CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"FameWave","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"FameWave \/ Kitov Pharma","highestDevelopmentStatusID":"6","companyTruncated":"FameWave \/ Kitov Pharma"},{"orgOrder":0,"company":"Kitov Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CM-24","moa":"CEACAM1","graph1":"Oncology","graph2":"Phase I","graph3":"Kitov Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kitov Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kitov Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MGD013","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MGD013","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HS-130","moa":"||T-cell mediated immune response","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Provectus Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rose Bengal Sodium","moa":"||Immunogenic apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Provectus Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intralesional Injection","sponsorNew":"Provectus Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Provectus Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medikine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medikine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/ Inapplicable"},{"orgOrder":0,"company":"Medikine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medikine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/ Inapplicable"},{"orgOrder":0,"company":"Medikine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medikine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/ Inapplicable"},{"orgOrder":0,"company":"Medikine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MDK-703","moa":"IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medikine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Medikine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medikine \/ Inapplicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA-4157","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Autolus Therapeutics \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Autolus Therapeutics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Immutep","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Large Molecule","year":"2021","type":"Collaboration","leadProduct":"CF33-CD19","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Imugene \/ Celularity","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Celularity"},{"orgOrder":0,"company":"Immutep","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftilagimod Alpha","moa":"||APC receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Immutep","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Immutep \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immutep \/ Inapplicable"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"AdAPT-001","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"Virogin Biotech","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"VG201","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Virogin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Virogin Biotech \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Virogin Biotech \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Biocytogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"YH001","moa":"||OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Eucure Biopharma \/ Biocytogen","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Biocytogen"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Syncromune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"YH002","moa":"OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Eucure Biopharma \/ Syncromune","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Syncromune"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"C5252","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"ImmVira","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"C5252","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmVira","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"ImmVira \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmVira \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Medison Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Medison Pharma"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"National Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Borealis Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Borealis Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Borealis Ventures"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"ANK-101","moa":"Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CLN-617","moa":"||IL-2\/IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CLN-617","moa":"IL-2\/IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ankyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Cytokine","graph1":"Oncology","graph2":"Phase I","graph3":"Ankyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Ankyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ankyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CLN-617","moa":"||IL-2\/IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Replimune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Replimune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Replimune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Replimune \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"SYNB1891","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CF33-hNIS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Imugene \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ City of Hope"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Air \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Air \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Beyond Air","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Beyond Air","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Beyond Air"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Stanford Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Stanford Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Stanford Medicine"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Advantech Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Advantech Capital","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Advantech Capital"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ONM-501","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Immatics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"177-Lu DOTA","moa":"||GD2","graph1":"Oncology","graph2":"Phase I","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Isotope Technologies Munich \/ Y-mAbs Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Isotope Technologies Munich \/ Y-mAbs Therapeutics"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Etakafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"Etakafusp Alpha","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SNK02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"23ME-01473","moa":"ULBP6","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"23andMe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"23ME-00610","moa":"CD200R1","graph1":"Oncology","graph2":"Phase I","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"23andMe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"23andMe \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Inapplicable"},{"orgOrder":0,"company":"ALX Oncology","sponsor":"Vivo Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series C Financing","leadProduct":"Evorpacept","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"ALX Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ALX Oncology \/ Vivo Capital","highestDevelopmentStatusID":"6","companyTruncated":"ALX Oncology \/ Vivo Capital"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Etakafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Asher Biotherapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Series C Financing","leadProduct":"Etakafusp Alpha","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Asher Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Asher Biotherapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Asher Biotherapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Bio4t2","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"B4T2-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bio4t2","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio4t2 \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio4t2 \/ Inapplicable"},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"CRX100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CRX100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CRX100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioEclipse Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"CRX100","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BioEclipse Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioEclipse Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioEclipse Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Orionis Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORB-011","moa":"cDC1 dendritic cell","graph1":"Oncology","graph2":"Phase I","graph3":"ChemDiv","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ChemDiv \/ Orionis Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"ChemDiv \/ Orionis Biosciences"},{"orgOrder":0,"company":"EpicentRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RRx-001","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"EpicentRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"EpicentRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EpicentRx \/ Inapplicable"},{"orgOrder":0,"company":"IconOVir Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"ICVB-1042","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IconOVir Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IconOVir Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IconOVir Bio \/ Inapplicable"},{"orgOrder":0,"company":"IconOVir Bio","sponsor":"UroGen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Acquisition","leadProduct":"ICVB-1042","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IconOVir Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IconOVir Bio \/ UroGen Pharma","highestDevelopmentStatusID":"6","companyTruncated":"IconOVir Bio \/ UroGen Pharma"},{"orgOrder":0,"company":"ImaginAb","sponsor":"DynamiCure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"DCBY02","moa":"CD93","graph1":"Oncology","graph2":"Phase I","graph3":"ImaginAb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImaginAb \/ DynamiCure","highestDevelopmentStatusID":"6","companyTruncated":"ImaginAb \/ DynamiCure"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"INKmune","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"Autogene Cevumeran","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ BioNTech"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"Autogene Cevumeran","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ BioNTech"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SNK02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pionyr Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synthorx Inc","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"THOR-707","moa":"Non-alpha-IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Synthorx Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Synthorx Inc \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Synthorx Inc \/ Sanofi"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vudalimab","moa":"PD-1\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vudalimab","moa":"PD-1\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Vudalimab","moa":"PD-1\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"IconOVir Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"ICVB-1042","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"IconOVir Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IconOVir Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IconOVir Bio \/ Inapplicable"},{"orgOrder":0,"company":"Coordination Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Coordination Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Coordination Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coordination Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Lu","moa":"uPAR","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Lu","moa":"uPAR","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CQDM","sponsor":"Quebec Breast Cancer Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Funding","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CQDM","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CQDM \/ Quebec Breast Cancer Foundation","highestDevelopmentStatusID":"6","companyTruncated":"CQDM \/ Quebec Breast Cancer Foundation"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2021","type":"Agreement","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Piramal Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Piramal Pharma Solutions"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ PPD"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab Zovodotin","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab Zovodotin","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Zanidatamab Zovodotin","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BC3195","moa":"CDH3\/P-cadherin","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCity Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"BC3195","moa":"||CDH3\/P-cadherin","graph1":"Oncology","graph2":"Phase I","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioCity Biopharma \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"BioCity Biopharma \/ Merck & Co"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"YH001","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biocytogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biocytogen \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8006","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BAT8009","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Aveo Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Termination","leadProduct":"AV-203","moa":"ErbB3","graph1":"Oncology","graph2":"Phase I","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Aveo Oncology","highestDevelopmentStatusID":"6","companyTruncated":"CANbridge Pharmaceuticals \/ Aveo Oncology"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CS2009","moa":"PD-1\/VEGF\/CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"DB-1312","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"DB-1312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ES014","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"Elpiscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ES009","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Elpiscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Elpiscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elpiscience \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"HF158K1","moa":"ErbB2","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"PML-RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tretinoin","moa":"PML-RAR-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TJ-L14B","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IBI319","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IBI321","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Letaplimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI110","moa":"||LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IBI319","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IBI318","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IBI939","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"JS006","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Junshi Biosciences \/ Coherus Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Junshi Biosciences \/ Coherus Biosciences"},{"orgOrder":0,"company":"Tianweiyuanhe Biomedical","sponsor":"3E Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"A-319","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tianweiyuanhe Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tianweiyuanhe Biomedical \/ 3E Bioventures","highestDevelopmentStatusID":"6","companyTruncated":"Tianweiyuanhe Biomedical \/ 3E Bioventures"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MSB2311","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Duality Biologics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"DB-1312","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Duality Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Duality Biologics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Duality Biologics \/ BeiGene"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"Onxeo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase I","graph3":"Onxeo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Onxeo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onxeo \/ Inapplicable"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"BI 754091","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI 765063","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BI 754091","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"PEP-010","moa":"Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pierre Fabre \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pierre Fabre \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"COM503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Gilead Sciences"},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"COM503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Gilead Sciences"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"BAY1905254","moa":"ILDR2","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"COM503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"COM503","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Gilead Sciences"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"DS-1055","moa":"Anti-glycoprotein A repetitions predominant","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"BYON3521","moa":"c-Met receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Dutch Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Funding","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Dutch Government","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Dutch Government"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"InteRNA Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"INT-1B3","moa":"Adenosine A2A receptor","graph1":"Oncology","graph2":"Phase I","graph3":"InteRNA Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InteRNA Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InteRNA Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Petosemtamab","moa":"EGFR\/LGR5","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Inapplicable"},{"orgOrder":0,"company":"Merus","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Merus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merus \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Merus \/ Incyte Corporation"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"CTM-N2D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CytoMed Therapeutics \/ Benchmark Company","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ Benchmark Company"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CTM-N2D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CytoMed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"SunAct Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"CTM-N2D","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CytoMed Therapeutics \/ SunAct Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ SunAct Cancer Institute"},{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EBC-129","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Experimental Drug Development Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Experimental Drug Development Centre \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Experimental Drug Development Centre \/ Inapplicable"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Ellipses Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"GENA-104","moa":"CNTN4","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genome & Company \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Ellipses Pharma"},{"orgOrder":0,"company":"OSR Holdings","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"BAL0891","moa":"||Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"OSR Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSR Holdings \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"OSR Holdings \/ SillaJen, Inc"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Oncomatryx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncomatryx \/ Inapplicable"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"CDTI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2025","type":"Financing","leadProduct":"OMTX705","moa":"||FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Oncomatryx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ CDTI","highestDevelopmentStatusID":"6","companyTruncated":"Oncomatryx \/ CDTI"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PM534","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaMar \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PharmaMar \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Aptevo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Aptevo Therapeutics"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1015","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1015","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1015","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ATOR-1015","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"BioInvent","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"DS-1055","moa":"Anti-glycoprotein A repetitions predominant","graph1":"Oncology","graph2":"Phase I","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioInvent \/ Daiichi Sankyo","highestDevelopmentStatusID":"6","companyTruncated":"BioInvent \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Birinapant","moa":"||SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ALG.APV-527","moa":"4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Birinapant","moa":"||SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BAL0891","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"BerGenBio ASA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||AXL receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ BerGenBio ASA","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ BerGenBio ASA"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Camidanlumab Tesirine","moa":"||CD25","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ADC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Camidanlumab Tesirine","moa":"CD25","graph1":"Oncology","graph2":"Phase I","graph3":"ADC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ADC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"BAL0891","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ SillaJen, Inc"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Pembrolizumab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Pierre Fabre"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"BAL0891","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Basilea Pharmaceutica \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ SillaJen, Inc"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Abcam","sponsor":"Pionyr","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"PY314","moa":"TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Abcam","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abcam \/ Pionyr","highestDevelopmentStatusID":"6","companyTruncated":"Abcam \/ Pionyr"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MTL-CEBPA","moa":"||C\/EBP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"MEN1309","moa":"||CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MEN1309","moa":"||CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"MEN1309","moa":"CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IMM60","moa":"||CD1d","graph1":"Oncology","graph2":"Phase I","graph3":"Portage Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Portage Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Portage Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"MEN1309","moa":"||CD205","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biotherapeutics \/ Agenus","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Agenus"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Saposin C","moa":"S1P receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Saposin C","moa":"S1P receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"LNCB74","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"LNCB74","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ONC-841","moa":"Siglec-10","graph1":"Oncology","graph2":"Phase I","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoC4 \/ Inapplicable"},{"orgOrder":0,"company":"OncoC4","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ONC-841","moa":"Siglec-10","graph1":"Oncology","graph2":"Phase I","graph3":"OncoC4","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OncoC4 \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OncoC4 \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Sensei Biotherapeutics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"SNS-101","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Sensei Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sensei Biotherapeutics \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Sensei Biotherapeutics \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CI-8993","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Termination","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Balstilimab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Botensilimab","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Credit Suisse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"CTX-471","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Credit Suisse","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Credit Suisse"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CTX-471","moa":"||CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CTX-471","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Olivia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Private Placement","leadProduct":"CTX-471","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Olivia Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Olivia Ventures"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"CTX-471","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compass Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Curis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CI-8993","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Curis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Curis \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ABBV-303","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dragonfly Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Expanded Collaboration","leadProduct":"MK-4464","moa":"||NK cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dragonfly Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"DynamiCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DCBY02","moa":"CD93","graph1":"Oncology","graph2":"Phase I","graph3":"DynamiCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DynamiCure \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"DynamiCure \/ Inapplicable"},{"orgOrder":0,"company":"DynamiCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"DCBY02","moa":"CD93","graph1":"Oncology","graph2":"Phase I","graph3":"DynamiCure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"DynamiCure \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"DynamiCure \/ Inapplicable"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"GV20-0251","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GV20 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GV20 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"GV20-0251","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GV20 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"GV20 Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Foundery Immune Studio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"PY314","moa":"TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ikena Oncology \/ Foundery Immune Studio","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Foundery Immune Studio"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JTX-8064","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JTX-8064","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"JTX-8064","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jounce Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Porustobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Porustobart","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Porustobart","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nona Biosciences \/ SK Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ SK Holdings"},{"orgOrder":0,"company":"Orionis Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORB-011","moa":"cDC1 dendritic cell","graph1":"Oncology","graph2":"Phase I","graph3":"Orionis Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orionis Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orionis Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"SQZ Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SQZ Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SQZ Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SQZ Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"XTX301","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xilio Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Xilio Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"XTX301","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xilio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xilio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xilio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"AGEN1777","moa":"TIGIT\/CD96","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Agenus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Imm Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Series B Financing","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orum Therapeutics \/ Imm Investment","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Imm Investment"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"University of Minnesota \/ Carisma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"University of Minnesota \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Celldex Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CDX-527","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Celldex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Celldex Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Celldex Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB1908","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Alpine Immune Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Alpine Immune Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Alpine Immune Sciences"},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Guangzhou-Israel Biotechnology Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"NTX-1088","moa":"||CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nectin Therapeutics \/ Guangzhou-Israel Biotechnology Fund","highestDevelopmentStatusID":"6","companyTruncated":"Nectin Therapeutics \/ Guangzhou-Israel Biotechnology Fund"},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NTX-1088","moa":"||CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nectin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nectin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nectin Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"NTX-1088","moa":"||CD155","graph1":"Oncology","graph2":"Phase I","graph3":"Nectin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nectin Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Nectin Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MiNK Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AgenT-797","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MiNK Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MiNK Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MiNK Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phosplatin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imifoplatin","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Phosplatin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phosplatin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phosplatin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VIP236","moa":"Alpha-V-beta-3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VIP236","moa":"Alpha-V-beta-3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VIP236","moa":"Alpha-V-beta-3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"VIP236","moa":"Alpha-V-beta-3 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Leerink Partners","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Leerink Partners"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"IP Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ IP Group","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ IP Group"},{"orgOrder":0,"company":"Carisma Therapeutics","sponsor":"Symbiosis II, LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"CT-0508","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Carisma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Carisma Therapeutics \/ Symbiosis II, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Carisma Therapeutics \/ Symbiosis II, LLC"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Birinapant","moa":"SMAC","graph1":"Oncology","graph2":"Phase I","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TetraLogic Pharmaceuticals \/ Medivir","highestDevelopmentStatusID":"6","companyTruncated":"TetraLogic Pharmaceuticals \/ Medivir"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BI 765063","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"BI 765063","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"MT-5111","moa":"Ribosome inactivation","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"MT-5111","moa":"Ribosome inactivation","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Davoceticept","moa":"||CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Davoceticept","moa":"CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Davoceticept","moa":"CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Davoceticept","moa":"CD28","graph1":"Oncology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alpine Immune Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seagen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seagen \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IGM-8444","moa":"DR5","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IGM-7354","moa":"IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"IGM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"IGM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IGM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Pembrolizumab","moa":"||TREM1","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pionyr Immunotherapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TREM1","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pionyr Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"SPX-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SparX Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"SparX Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPX-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SparX Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SparX Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SparX Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FPI-2058","moa":"||Neurotensin type-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fusion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fusion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"AK127","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AK127","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"ATG-101","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8008","moa":"Trop2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"CS1002","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CStone Pharmaceuticals \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"CICC Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"GT101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GRIT Biotechnology \/ CICC Capital","highestDevelopmentStatusID":"6","companyTruncated":"GRIT Biotechnology \/ CICC Capital"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||TNF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Bright Peak Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"LZM009","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Livzon Pharmaceutical Group \/ Bright Peak Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Livzon Pharmaceutical Group \/ Bright Peak Therapeutics"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"9MW3811","moa":"IL-11 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"QureBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"QureBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"QureBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QureBio \/ Inapplicable"},{"orgOrder":0,"company":"QureBio Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Q-1802","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"QureBio Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"QureBio Ltd. \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QureBio Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HLX22","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NWY001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Adcendo","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"ADCE-T02","moa":"Tissue factor","graph1":"Oncology","graph2":"Phase I","graph3":"Adcendo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adcendo \/ TCGX","highestDevelopmentStatusID":"6","companyTruncated":"Adcendo \/ TCGX"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Finland\u2019s Lifeline Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"Avelumab","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Finland\u2019s Lifeline Ventures","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Finland\u2019s Lifeline Ventures"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Igrelimogene Litadenorepvec","moa":"TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Lifeline Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Lifeline Ventures","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Lifeline Ventures"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"IPH5201","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innate Pharma \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IPH5201","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HMPL-A83","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM902","moa":"TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"NeoTX Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"Durvalumab","moa":"||5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"NeoTX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeoTX Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"NeoTX Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Kling Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KBA1412","moa":"||CD9","graph1":"Oncology","graph2":"Phase I","graph3":"Kling Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kling Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kling Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synaffix","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"IBI343","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Synaffix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Synaffix \/ Innovent Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Synaffix \/ Innovent Biologics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Laekna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"FAZ053","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Laekna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Laekna Therapeutics"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ACE1702","moa":"HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Ridgeback Capital Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"ACE1702","moa":"HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Ridgeback Capital Investments","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Ridgeback Capital Investments"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iontas","sponsor":"F-star Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Iontas \/ F-star Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Iontas \/ F-star Therapeutics"},{"orgOrder":0,"company":"Poolbeg Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"POLB 001","moa":"MAPK\/p38","graph1":"Oncology","graph2":"Phase I","graph3":"Poolbeg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Poolbeg Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poolbeg Pharma \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FS222","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HBM1020","moa":"B7-H7","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"AGEN2373","moa":"||CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Agenus \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Gilead Sciences"},{"orgOrder":0,"company":"Jounce Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"GS-1811","moa":"||TITR cell","graph1":"Oncology","graph2":"Phase I","graph3":"Jounce Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Jounce Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Jounce Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"XMT-2056","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"XMT-2056","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Cullinan Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Cullinan Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Cullinan Therapeutics"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"HBM7008","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HBM1020","moa":"B7-H7","graph1":"Oncology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Bank Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Bank Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SB 11285","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Bank Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spring Bank Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SB 11285","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"Spring Bank Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Spring Bank Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spring Bank Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"||IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Casdozokitug","moa":"IL-27 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Niowave","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Collaboration","leadProduct":"225-Ac FPI-1434","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Niowave","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Niowave \/ Fusion Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Niowave \/ Fusion Pharma"},{"orgOrder":0,"company":"Seven and Eight Biopharmaceuticals","sponsor":"Eikon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"BDB018","moa":"||Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Seven and Eight Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seven and Eight Biopharmaceuticals \/ Eikon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Seven and Eight Biopharmaceuticals \/ Eikon Therapeutics"},{"orgOrder":0,"company":"Seven and Eight Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like-7\/Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Seven and Eight Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seven and Eight Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seven and Eight Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"||GRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"PEEL Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PEEL-224","moa":"Topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"PEEL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PEEL Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEEL Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Peter MacCallum Cancer Centre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Partnership","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Peter MacCallum Cancer Centre","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Peter MacCallum Cancer Centre"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2020","type":"Financing","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Propanc Biopharma","sponsor":"University of Jaen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"Chymotrypsinogen","moa":"||Chymotrypsinogen","graph1":"Oncology","graph2":"Phase I","graph3":"Propanc Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Propanc Biopharma \/ University of Jaen","highestDevelopmentStatusID":"6","companyTruncated":"Propanc Biopharma \/ University of Jaen"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NL-201","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NL-201","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NL-201","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neoleukin Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NL-201","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Neoleukin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Neoleukin Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neoleukin Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"Medigene","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ BioNTech","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ BioNTech"},{"orgOrder":0,"company":"Medigene","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Medigene","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ 2Seventy Bio","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ 2Seventy Bio"},{"orgOrder":0,"company":"Medigene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PD1-41BB switch receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medigene \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TPST-1495","moa":"PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CCX559","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CCX559","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Cleave Therapeutics","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CB-5339 Tosylate","moa":"VCP\/p97","graph1":"Oncology","graph2":"Phase I","graph3":"Cleave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cleave Therapeutics \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cleave Therapeutics \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivoceranib","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Elevar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elevar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elevar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ERAS-601","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Docetaxel","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnate Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Kinnjiu Biopharma","sponsor":"Kinnate Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exarafenib","moa":"||RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnjiu Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kinnjiu Biopharma \/ Kinnate Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Kinnjiu Biopharma \/ Kinnate Biopharma"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"CD8","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PACT Pharma \/ Vida Ventures LLC","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharma \/ Vida Ventures LLC"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amezalpat","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TPST-1495","moa":"PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TPX0022","moa":"CSF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TPX0022","moa":"CSF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TPX0022","moa":"CSF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Turning Point Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Turning Point Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CCX559","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AMG 193","moa":"||MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Amgen Inc"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ GSK"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Synthetic Lethality","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"IDE397","moa":"MAT2A","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ideaya Biosciences \/ Synthetic Lethality","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Synthetic Lethality"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rucaparib Camsylate","moa":"||PARP-1\/2\/3","graph1":"Oncology","graph2":"Phase I","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Clovis Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clovis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"PRT543","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATG-017","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palupiprant","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adlai Nortye \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nortye \/ Merck & Co"},{"orgOrder":0,"company":"Antengene","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATG-017","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ AstraZeneca"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATG-018","moa":"ATR","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATG-037","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATG-019","moa":"||PAK4","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"Antengene","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"ATG-037","moa":"||CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BGB-3245","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BGB-15025","moa":"||HPK1","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLR2007","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ICP-189","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"INV-1120","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ionova Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionova Life Science \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Ionova Life Science \/ Merck & Co"},{"orgOrder":0,"company":"Ionova Life Science","sponsor":"Tsing Song Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"INV-1120","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ionova Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionova Life Science \/ Tsing Song Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionova Life Science \/ Tsing Song Capital"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JAB-2485","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"Jacobio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jacobio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jacobio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Sanyou Biopharmaceuticals \/ Hangzhou Zhongmei Huadong Pharmaceutical"},{"orgOrder":0,"company":"Xiamen Biotime Biotechnology","sponsor":"Adlai Nortye","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"AN4005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Xiamen Biotime Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xiamen Biotime Biotechnology \/ Adlai Nortye","highestDevelopmentStatusID":"6","companyTruncated":"Xiamen Biotime Biotechnology \/ Adlai Nortye"},{"orgOrder":0,"company":"Zion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZN-A-1041","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Zion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Sinorda Biomedicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sanyou Biopharmaceuticals \/ Sinorda Biomedicine","highestDevelopmentStatusID":"6","companyTruncated":"Sanyou Biopharmaceuticals \/ Sinorda Biomedicine"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"5-Methyltetrazole","moa":"A2AR\/BR","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Domain Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Phost'in Therapeutics","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"PhOx430","moa":"GnT-V","graph1":"Oncology","graph2":"Phase I","graph3":"Phost'in Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phost'in Therapeutics \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Phost'in Therapeutics \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"NMS-03305293","moa":"PARP-1","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Chordia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CTX-712","moa":"CLK kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Chordia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chordia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chordia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"NECVAX-NEO1","moa":"Cytotoxic T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NEC Corporation \/ AGC Biologics","highestDevelopmentStatusID":"6","companyTruncated":"NEC Corporation \/ AGC Biologics"},{"orgOrder":0,"company":"Sumitomo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo \/ Inapplicable"},{"orgOrder":0,"company":"Nykode Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Nykode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nykode Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Nykode Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"HANDOK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM601","moa":"TRKA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ HANDOK","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ HANDOK"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AUM601","moa":"TRKA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Duke-Nus Medical School","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ETC-159","moa":"||Wnt signalling pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Duke-Nus Medical School","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Duke-Nus Medical School \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Duke-Nus Medical School \/ Inapplicable"},{"orgOrder":0,"company":"HANDOK","sponsor":"AUM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"CHC2014","moa":"Pan-TRK","graph1":"Oncology","graph2":"Phase I","graph3":"HANDOK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"HANDOK \/ AUM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"HANDOK \/ AUM Biosciences"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Roginolisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ INKEF Capital","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ INKEF Capital"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"TNO155","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"GT Apeiron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ GT Apeiron Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ GT Apeiron Therapeutics"},{"orgOrder":0,"company":"Exscientia","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Merck Group"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sanofi"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sanofi"},{"orgOrder":0,"company":"Exscientia","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AZD5305","moa":"PARP-1","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"A2AR","graph1":"Oncology","graph2":"Phase I","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exscientia \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Exscientia \/ Evotec"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RXC004","moa":"Porcupine","graph1":"Oncology","graph2":"Phase I","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Inapplicable"},{"orgOrder":0,"company":"Rise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"R-5780","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Rise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ DCVC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ DCVC Bio"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IK-175","moa":"AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IK-175","moa":"AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IK-175","moa":"AHR","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Cullgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Merger","leadProduct":"CG001419","moa":"TRK receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pulmatrix \/ Cullgen","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Cullgen"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"RLY-1971","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RBN-2397","moa":"PARP-7","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RBN-2397","moa":"PARP-7","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ribon Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"RBN-2397","moa":"PARP-7","graph1":"Oncology","graph2":"Phase I","graph3":"Ribon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ribon Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Ribon Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||PKM1\/PKM2","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TP-1454","moa":"PKM1\/PKM2","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dubermatinib","moa":"AXL tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SY-5609","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SY-5609","moa":"CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"GDC-6036","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Genentech"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Tempest Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"TPST-1495","moa":"PGE2","graph1":"Oncology","graph2":"Phase I","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Millendo Therapeutics \/ Tempest Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Millendo Therapeutics \/ Tempest Therapeutics"},{"orgOrder":0,"company":"ImmunSYS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunSYS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunSYS \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunSYS \/ Inapplicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASN007","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asana BioSciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asana BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/Src-family kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BTX-1188","moa":"GSPT1 protein","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Inapplicable"},{"orgOrder":0,"company":"Owkin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OKN4395","moa":"||EP2\/EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Owkin","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Owkin \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Owkin \/ Inapplicable"},{"orgOrder":0,"company":"Rgenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RGX-104","moa":"Liver X receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Rgenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rgenix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rgenix \/ Inapplicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"RAGE","graph1":"Oncology","graph2":"Phase I","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"vTv Therapeutics \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"vTv Therapeutics \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Broad Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Broad Institute","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Broad Institute"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Broad Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bayer AG \/ Broad Institute","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Broad Institute"},{"orgOrder":0,"company":"NCCN Oncology Research Program","sponsor":"Taiho Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Futibatinib","moa":"||FGFR","graph1":"Oncology","graph2":"Phase I","graph3":"NCCN Oncology Research Program","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NCCN Oncology Research Program \/ Taiho Oncology","highestDevelopmentStatusID":"6","companyTruncated":"NCCN Oncology Research Program \/ Taiho Oncology"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Slate Path Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"TTI-101","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ Slate Path Capital","highestDevelopmentStatusID":"6","companyTruncated":"Tvardi Therapeutics \/ Slate Path Capital"},{"orgOrder":0,"company":"Apollomics Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"APL-102","moa":"VEGF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Apollomics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Apollomics Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Apollomics Inc \/ Inapplicable"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"ABBV-CLS-579","moa":"PTPN2","graph1":"Oncology","graph2":"Phase I","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calico Life Sciences \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Calico Life Sciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Plexium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PLX-4545","moa":"IKZF2","graph1":"Oncology","graph2":"Phase I","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Plexium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Plexium \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Mabwell Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Mabwell Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Mabwell Bioscience"},{"orgOrder":0,"company":"Trethera","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Cancer Institute"},{"orgOrder":0,"company":"Trethera","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"TRE-515","moa":"dCK","graph1":"Oncology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ National Eye Institute","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ National Eye Institute"},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VT3989","moa":"TEAD palmitoylation","graph1":"Oncology","graph2":"Phase I","graph3":"Vivace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vivace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABBV-CLS-484","moa":"||PTPN1\/PTPN2","graph1":"Oncology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Canadian Cancer Trials Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lunresertib","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Canadian Cancer Trials Group","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Canadian Cancer Trials Group"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lunresertib","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lunresertib","moa":"PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ABM-1310","moa":"BRAF","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-168","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Utidelone","moa":"Microtubule","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Utidelone","moa":"Microtubule","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"JS InnoPharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPharm \/ Inapplicable"},{"orgOrder":0,"company":"JS InnoPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"JSI-1187","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"JS InnoPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"JS InnoPharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JS InnoPharm \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dovitinib","moa":"||Pan-TKI","graph1":"Oncology","graph2":"Phase I","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-9081","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DT-9081","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IPN60090","moa":"||Glutaminase-1","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-9081","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Panacea Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"DT-9081","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Panacea Venture"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HMPL-415S1","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hutchmed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hutchmed \/ Inapplicable"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genome & Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Inapplicable"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genome & Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Inapplicable"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Genome & Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genome & Company \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Debio 0123","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"STC-15","moa":"METTL3","graph1":"Oncology","graph2":"Phase I","graph3":"Storm Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Storm Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Storm Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foundation Medicine","sponsor":"Repare Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Lunresertib","moa":"||PKMYT1","graph1":"Oncology","graph2":"Phase I","graph3":"Foundation Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Foundation Medicine \/ Repare Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Foundation Medicine \/ Repare Therapeutics"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"KSQ-4279","moa":"USP-1","graph1":"Oncology","graph2":"Phase I","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KSQ Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"KSQ Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KSQ-4279","moa":"||USP-1","graph1":"Oncology","graph2":"Phase I","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KSQ-4279","moa":"||USP-1","graph1":"Oncology","graph2":"Phase I","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KSQ Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KSQ Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HC-5404","moa":"PERK","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EVT801","moa":"VEGF3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EVT801","moa":"VEGF3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Evotec","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVT801","moa":"VEGF3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EVT801","moa":"VEGF3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"HanX Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ HanX Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ HanX Biopharmaceuticals"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"CDK4\/6","graph1":"Oncology","graph2":"Phase I","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ CPRIT","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ CPRIT"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"7 Hills Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alintegimod","moa":"Integrin-alpha-4\/beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"7 Hills Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"7 Hills Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"7 Hills Pharma \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HC-7366","moa":"GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule, Immediate Release","sponsorNew":"HiberCell \/ Labcorp Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Labcorp Drug Development"},{"orgOrder":0,"company":"ProBioGen","sponsor":"ImmunOs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2023","type":"Partnership","leadProduct":"IOS-1002","moa":"||LILRB1\/LILRB2\/KIR3DL1","graph1":"Oncology","graph2":"Phase I","graph3":"ProBioGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ProBioGen \/ ImmunOs Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"ProBioGen \/ ImmunOs Therapeutics"},{"orgOrder":0,"company":"Invios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Invios \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"ABL Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"I-Mab Biopharma \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ ABL Bio"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"MaxCyte \/ Apeiron Biologics","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Apeiron Biologics"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SRF617","moa":"CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Surface Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Merck & Co \/ Surface Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Surface Oncology"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Cancer Focus Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ImmunoGenesis \/ Cancer Focus Fund","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Cancer Focus Fund"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ImmunoGenesis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ImmunoGenesis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ImmunoGenesis \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ImmunoGenesis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IMGS-001","moa":"PD-L1\/PD-L2","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoGenesis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ImmunoGenesis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mifepristone","moa":"||Glucocorticoid\/progesterone receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Cure Stat Rx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Collaboration","leadProduct":"Mifepristone","moa":"||Glucocorticoid\/progesterone receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Therapeutic Solutions \/ Cure Stat Rx","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Cure Stat Rx"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revolution Medicines \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ J.P. Morgan"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VVD-130037","moa":"KEAP1","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vividion Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Vividion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vividion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vividion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synnovation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SNV1521","moa":"PARP-1","graph1":"Oncology","graph2":"Phase I","graph3":"Synnovation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Synnovation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synnovation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synnovation Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fulvestrant","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Synnovation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Synnovation Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synnovation Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Synnovation Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"SNV1521","moa":"PARP-1","graph1":"Oncology","graph2":"Phase I","graph3":"Synnovation Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Synnovation Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Synnovation Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"Eisai","sponsor":"Prism Biolab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"E7386","moa":"||CBP\/beta-catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ Prism Biolab","highestDevelopmentStatusID":"6","companyTruncated":"Eisai \/ Prism Biolab"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Omega Funds","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Omega Funds"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DCC-3116","moa":"ULK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DCC-3116","moa":"ULK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deciphera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Monopteros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MPT-0118","moa":"||MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"Monopteros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monopteros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopteros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopteros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MPT-0118","moa":"||MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"Monopteros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Monopteros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopteros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ikena Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IK-930","moa":"||TEAD","graph1":"Oncology","graph2":"Phase I","graph3":"Ikena Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ikena Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ikena Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Forma Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BI 1701963","moa":"Pan-KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Forma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Forma Therapeutics"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"STK-012","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Deerfield Management","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Deerfield Management"},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AMV564","moa":"||MDSCs","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AMV564","moa":"MDSCs","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amphivena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AMV564","moa":"MDSCs","graph1":"Oncology","graph2":"Phase I","graph3":"Amphivena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amphivena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amphivena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"MK-1484","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sutro Biopharma \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck & Co"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Inapplicable"},{"orgOrder":0,"company":"Synthekine","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Series C Financing","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ The Column Group"},{"orgOrder":0,"company":"Synthekine","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series A Financing","leadProduct":"STK-012","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Synthekine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Synthekine \/ Canaan Partners","highestDevelopmentStatusID":"6","companyTruncated":"Synthekine \/ Canaan Partners"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ University of Minnesota","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biologics \/ University of Minnesota"},{"orgOrder":0,"company":"HCW Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"HCW9218","moa":"TGF-beta-2","graph1":"Oncology","graph2":"Phase I","graph3":"HCW Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HCW Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HCW Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SW1115C3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stemirna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stemirna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"DK210","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Deka Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DK210","moa":"||EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Deka Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Deka Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Deka Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elicio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Elicio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Elicio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elicio Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan Capital Markets","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Chardan Capital Markets"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Chardan Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Chardan Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Chardan Healthcare"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Janssen Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Agreement","leadProduct":"SON-1010","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sonnet BioTherapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IMA401","moa":"MAGE-A4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IMA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"IMA201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IMA202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"IMA401","moa":"MAGE-A4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IMA401","moa":"MAGE-A4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Medigene","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medigene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigene \/ EpimAb Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Medigene \/ EpimAb Biotherapeutics"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Elsa Eckert Life Science Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Pentixafor","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Elsa Eckert Life Science Accelerator","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPharm \/ Elsa Eckert Life Science Accelerator"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETX-19477","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"858 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"858 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"858 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"ACTM-838","moa":"IL-15plex\/eSTING","graph1":"Oncology","graph2":"Phase I","graph3":"Actym Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actym Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Actym Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IO-108","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Cemiplimab","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT199","moa":"CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"TTX-080","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tizona Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TTX-080","moa":"HLA-G","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tizona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"858 Therapeutics","sponsor":"Avidity Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"ETX-19477","moa":"PARG","graph1":"Oncology","graph2":"Phase I","graph3":"858 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"858 Therapeutics \/ Avidity Partners","highestDevelopmentStatusID":"6","companyTruncated":"858 Therapeutics \/ Avidity Partners"},{"orgOrder":0,"company":"Actym Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACTM-838","moa":"IL-15plex\/eSTING","graph1":"Oncology","graph2":"Phase I","graph3":"Actym Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actym Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Actym Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ADRX-0706","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adcentrx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adcentrx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Financing","leadProduct":"ARX788","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ambrx Inc \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"6","companyTruncated":"Ambrx Inc \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Zhejiang Medicine Co Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"ARX305","moa":"CD70","graph1":"Oncology","graph2":"Phase I","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ambrx Inc \/ Zhejiang Medicine Co Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Ambrx Inc \/ Zhejiang Medicine Co Ltd"},{"orgOrder":0,"company":"BridgeBio Oncology Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BBO-10203","moa":"||PI3K-alpha\/RAS","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Oncology Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Oncology Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Oncology Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BBP-398","moa":"SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SVF-CAL1","moa":"Immunostimulant","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CID-078","moa":"Cyclin A\/Cyclin B RxL","graph1":"Oncology","graph2":"Phase I","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circle Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Circle Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Circle Pharma","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series D Financing","leadProduct":"CID-078","moa":"Cyclin A\/Cyclin B RxL","graph1":"Oncology","graph2":"Phase I","graph3":"Circle Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circle Pharma \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Circle Pharma \/ The Column Group"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CX-904","moa":"EGFR-CD3 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CX-801","moa":"||IFN-alpha-2b","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenVivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GVO-1102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GenVivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenVivo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GenVivo \/ Inapplicable"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"GIGA-564","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IO-108","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IO-108","moa":"LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IO-202","moa":"LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immune-Onc Therapeutics","sponsor":"Triwise Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"IO-108","moa":"||LILRB2","graph1":"Oncology","graph2":"Phase I","graph3":"Immune-Onc Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune-Onc Therapeutics \/ Triwise Capital","highestDevelopmentStatusID":"6","companyTruncated":"Immune-Onc Therapeutics \/ Triwise Capital"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"MBrace Therapeutics","sponsor":"TPG Life Sciences Innovations","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Series B Financing","leadProduct":"Monomethyl Auristatin E","moa":"EphA5 MMAE","graph1":"Oncology","graph2":"Phase I","graph3":"MBrace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MBrace Therapeutics \/ TPG Life Sciences Innovations","highestDevelopmentStatusID":"6","companyTruncated":"MBrace Therapeutics \/ TPG Life Sciences Innovations"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM831","moa":"||ILT-3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Cellares","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"NeoTCR-P1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PACT Pharma \/ Cellares","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharma \/ Cellares"},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NeoTCR-P1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PACT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"PACT Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NeoTCR-P1","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PACT Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PACT Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PACT Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Pathos","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"P-500","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Pathos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pathos \/ New Enterprise Associates","highestDevelopmentStatusID":"6","companyTruncated":"Pathos \/ New Enterprise Associates"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT199","moa":"||CD73","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PRTX007","moa":"Toll-like-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Primmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Primmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"M1231","moa":"MUC1-EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Merck Group"},{"orgOrder":0,"company":"Tizona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||HLA-G","graph1":"Oncology","graph2":"Phase I","graph3":"Tizona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tizona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tizona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Trishula Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ttx-030","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Trishula Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trishula Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trishula Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vincera Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Enitociclib","moa":"PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincera Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vincera Pharma \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Vincera Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"XmAb306","moa":"IL-15-beta-receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"XmAb306","moa":"IL-15-beta-receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NGM831","moa":"ILT-3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pheast Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PHST001","moa":"CD24","graph1":"Oncology","graph2":"Phase I","graph3":"Pheast Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pheast Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pheast Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"INCB123667","moa":"CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"P-500","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prelude Therapeutics \/ Pathos","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Pathos"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Olaparib","moa":"||Pol-theta ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CM369","moa":"CCR8","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Connoya Biomedical Technology","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Connoya Biomedical Technology"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Series D Financing","leadProduct":"Adg106","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adagene Suzhou Limited \/ General Atlantic","highestDevelopmentStatusID":"6","companyTruncated":"Adagene Suzhou Limited \/ General Atlantic"},{"orgOrder":0,"company":"BeiGene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BG-68501","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeiGene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BeiGene \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS014004","moa":"Type-2 c-met tyrosine kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8010","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"BAT8007","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BAT1308","moa":"||OX40 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"BJ Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"BJ-001","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BJ Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BJ Bioscience \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"BJ Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"CellOrigin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SY001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CellOrigin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CellOrigin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CellOrigin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"CS5001","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CStone Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CStone Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Lemzoparlimab","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ AbbVie Inc"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lemzoparlimab","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneOnco","sponsor":"Instil Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"IMM2510","moa":"PD-L1\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOnco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOnco \/ Instil Bio","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOnco \/ Instil Bio"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CM369","moa":"CCR8","graph1":"Oncology","graph2":"Phase I","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InnoCare Pharma \/ Connoya Biomedical Technology","highestDevelopmentStatusID":"6","companyTruncated":"InnoCare Pharma \/ Connoya Biomedical Technology"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI363","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"IBI389","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SHR-4849","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Ideaya Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Ideaya Biosciences"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HRS-1167","moa":"PARP-1","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Merck Group"},{"orgOrder":0,"company":"NanoMab","sponsor":"University Hospital Aachen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"NM-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"NanoMab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoMab \/ University Hospital Aachen","highestDevelopmentStatusID":"6","companyTruncated":"NanoMab \/ University Hospital Aachen"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"TST005","moa":"TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcenta Holding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cytune Pharma"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SOT201","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Sotio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Inapplicable"},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symphogen \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen \/ Servier"},{"orgOrder":0,"company":"Symphogen","sponsor":"Servier Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Sym021","moa":"PD-1","graph1":"Oncology","graph2":"Phase I","graph3":"Symphogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symphogen \/ Servier Canada","highestDevelopmentStatusID":"6","companyTruncated":"Symphogen \/ Servier Canada"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"IPH4502","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IPH4502","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Invectys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INVAC-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invectys \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invectys \/ Inapplicable"},{"orgOrder":0,"company":"Trigr","sponsor":"Compass Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"CTX-009","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Trigr","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trigr \/ Compass Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Trigr \/ Compass Therapeutics"},{"orgOrder":0,"company":"Aummune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AM003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aummune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aummune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aummune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BND-35","moa":"||LT3\/LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biond Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biond Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"BND-35","moa":"||LT3\/LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biond Biologics \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Biond Biologics \/ Merck Group"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"STA551","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pyrrolobenzodiazepine ADC","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Byondis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SYD1875","moa":"5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Byondis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Byondis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Byondis \/ Inapplicable"},{"orgOrder":0,"company":"Pepscan","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Pepscan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pepscan \/ Mayo Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Pepscan \/ Mayo Clinic"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"BH3120","moa":"||PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Merck & Co"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BH3120","moa":"||PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneOncia Therapeutics, Inc","sponsor":"3D Medicines Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"IMC-002","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuneOncia Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuneOncia Therapeutics, Inc \/ 3D Medicines Corporation","highestDevelopmentStatusID":"6","companyTruncated":"ImmuneOncia Therapeutics, Inc \/ 3D Medicines Corporation"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"ImmuneOncia Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"IMC-002","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ ImmuneOncia Therapeutics, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Biologics \/ ImmuneOncia Therapeutics, Inc"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"PMC-402","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ PharmAbcine","highestDevelopmentStatusID":"6","companyTruncated":"Samsung Biologics \/ PharmAbcine"},{"orgOrder":0,"company":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Celyvir","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas \/ Orgenesis","highestDevelopmentStatusID":"6","companyTruncated":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas \/ Orgenesis"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mitazalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Scandion Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Mitazalimab","moa":"||CD40","graph1":"Oncology","graph2":"Phase I","graph3":"Alligator Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alligator Bioscience \/ Scandion Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Alligator Bioscience \/ Scandion Oncology"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MP0310","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Partners \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Partners \/ Amgen Inc"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NM32-2668","moa":"ROR1\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FS120","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"FS120","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epsilogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"FS120","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"FS120","moa":"||CD137","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F-star Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Kings College London","sponsor":"Epsilogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kings College London \/ Epsilogen","highestDevelopmentStatusID":"6","companyTruncated":"Kings College London \/ Epsilogen"},{"orgOrder":0,"company":"Oxford Vacmedix","sponsor":"DxVx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"OVM-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Vacmedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Vacmedix \/ DxVx","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Vacmedix \/ DxVx"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OXL001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Cue Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"CUE-101","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Cue Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"University of Oxford \/ Cue Biopharma"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Oxilio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"OXL001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quotient Sciences \/ Oxilio","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Oxilio"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lorigerlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Angiex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"AGX101","moa":"TM4SF1","graph1":"Oncology","graph2":"Phase I","graph3":"Angiex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angiex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Angiex \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CLN-619","moa":"MICA\/MICB protein","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"SRF813","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ GSK"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"WTX-124","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"WTX-124","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AGEN1571","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"AGEN1223","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Sulanemadlin","moa":"MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aileron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Angiex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"AGX101","moa":"TM4SF1","graph1":"Oncology","graph2":"Phase I","graph3":"Angiex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angiex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Angiex \/ Inapplicable"},{"orgOrder":0,"company":"Boston Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"GSK3903371","moa":"IL-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Boston Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Pharmaceuticals \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Boston Pharmaceuticals \/ GSK"},{"orgOrder":0,"company":"Compass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Asciminib","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Compass Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cullinan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CLN-619","moa":"||MICA\/MICB protein","graph1":"Oncology","graph2":"Phase I","graph3":"Cullinan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cullinan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullinan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dragonfly Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DF6215","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dragonfly Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dragonfly Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dragonfly Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||DDR1","graph1":"Oncology","graph2":"Phase I","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incendia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incendia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Incendia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||DDR1","graph1":"Oncology","graph2":"Phase I","graph3":"Incendia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incendia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Incendia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MOMA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MOMA-313","moa":"Pol-theta","graph1":"Oncology","graph2":"Phase I","graph3":"MOMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MOMA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MOMA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SRK-181","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SRK-181","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"SRK-181","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Silicon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"Silicon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silicon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silicon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Dostarlimab","moa":"||PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ GSK"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SRF231","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Vigeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"VT1021","moa":"CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Vigeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VIC-1911","moa":"Aurora kinase A","graph1":"Oncology","graph2":"Phase I","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VITRAC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"VITRAC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agenus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AGEN1571","moa":"ILT-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agenus \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SRK-181","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-M17D1","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"ImmuNext Inc","sponsor":"Curis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Onvatilimab","moa":"VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"ImmuNext Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmuNext Inc \/ Curis","highestDevelopmentStatusID":"6","companyTruncated":"ImmuNext Inc \/ Curis"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Oncorus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Collaboration","leadProduct":"ONCR-177","moa":"||CTLA-4","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Oncorus","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Oncorus"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Irofulven","moa":"||DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"The Greehey Children's Cancer Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ The Greehey Children's Cancer Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ The Greehey Children's Cancer Research Institute"},{"orgOrder":0,"company":"Glytherix","sponsor":"SHINE Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"177-Lu DOTA Miltuximab","moa":"GPC1","graph1":"Oncology","graph2":"Phase I","graph3":"Glytherix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glytherix \/ SHINE Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Glytherix \/ SHINE Technologies"},{"orgOrder":0,"company":"Lirum Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Private Placement","leadProduct":"LX-101","moa":"IGF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lirum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lirum Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"Lirum Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PTX-35","moa":"TNFSF25 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PTX-35","moa":"TNFSF25 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heat Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"SL-172154","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shattuck Labs \/ Redmile Group","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Redmile Group"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BAY2416964","moa":"Aryl hydrocarbon receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Uzatresgene Autoleucel","moa":"MAGE-A4","graph1":"Oncology","graph2":"Phase I","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adaptimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KaliVir Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KaliVir Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"KaliVir Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"KaliVir Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KaliVir Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KaliVir Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tavotek Biotherapeutics","sponsor":"Yisheng Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Tavo-201","moa":"||CD4 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Tavotek Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tavotek Biotherapeutics \/ Yisheng Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Tavotek Biotherapeutics \/ Yisheng Biopharma"},{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Forbius","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AVID200","moa":"TGF-beta-1","graph1":"Oncology","graph2":"Phase I","graph3":"Forbius","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forbius \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Forbius \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Oranomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"212-Pb DOTAM-GRPR1","moa":"GRPr","graph1":"Oncology","graph2":"Phase I","graph3":"Oranomed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranomed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oranomed \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SBT6050","moa":"||Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SBT6050","moa":"Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SBT6050","moa":"Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pascal Biosciences","sponsor":"Sorse Technology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"PAS-393","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Pascal Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pascal Biosciences \/ Sorse Technology","highestDevelopmentStatusID":"6","companyTruncated":"Pascal Biosciences \/ Sorse Technology"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Series C Financing","leadProduct":"SBT6050","moa":"Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silverback Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"SBT6050","moa":"Toll-like-8 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Silverback Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Silverback Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silverback Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Invenra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||5T4 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Invenra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invenra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invenra \/ Inapplicable"},{"orgOrder":0,"company":"NiKang Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NKT3964","moa":"CDK2","graph1":"Oncology","graph2":"Phase I","graph3":"NiKang Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NiKang Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NiKang Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NG-641","moa":"AP\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Akamis Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Akamis Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"NG-350A","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Akamis Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Akamis Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Akamis Bio \/ Undisclosed"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||KIRS","graph1":"Oncology","graph2":"Phase I","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NKGen Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NKGen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Collaboration","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ Thinkequity","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ Thinkequity"},{"orgOrder":0,"company":"TransCode Therapeutics","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Public Offering","leadProduct":"TTX-MC138","moa":"miR-10b","graph1":"Oncology","graph2":"Phase I","graph3":"TransCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TransCode Therapeutics \/ WestPark Capital","highestDevelopmentStatusID":"6","companyTruncated":"TransCode Therapeutics \/ WestPark Capital"},{"orgOrder":0,"company":"Revolution Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vociprotafib","moa":"||SHP2","graph1":"Oncology","graph2":"Phase I","graph3":"Revolution Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Revolution Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Revolution Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Tachyon Therapeutics","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"Phase I","graph3":"Tachyon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tachyon Therapeutics \/ Cirm","highestDevelopmentStatusID":"6","companyTruncated":"Tachyon Therapeutics \/ Cirm"},{"orgOrder":0,"company":"Tachyon Therapeutics","sponsor":"Veblen Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"Phase I","graph3":"Tachyon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tachyon Therapeutics \/ Veblen Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tachyon Therapeutics \/ Veblen Ventures"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"N-Myc","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Institute of Cancer Research \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"The Institute of Cancer Research \/ Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"Athenex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Inapplicable"},{"orgOrder":0,"company":"Athenex","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ SVB Securities","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ SVB Securities"},{"orgOrder":0,"company":"Immunai","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Immunai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunai \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Immunai \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kuur Therapeutics \/ Athenex","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Athenex"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kuur Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"IP Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"CMD-501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kuur Therapeutics \/ IP Group","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ IP Group"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Opaganib","moa":"SPHK2","graph1":"Oncology","graph2":"Phase I","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivatrotamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kuur Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Seneca Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Licensing Agreement","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Seneca Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Seneca Therapeutics"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"National Institute for Biomedical Imaging and Bioengineering","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Molecular Targeting Technologies \/ National Institute for Biomedical Imaging and Bioengineering","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Targeting Technologies \/ National Institute for Biomedical Imaging and Bioengineering"},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"Phase I","graph3":"Seneca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seneca Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seneca Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seneca Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"SVV-001","moa":"TEM8","graph1":"Oncology","graph2":"Phase I","graph3":"Seneca Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Seneca Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seneca Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"Octreotide Acetate","moa":"SST receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Tidutamab","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tidutamab","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tidutamab","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Viewpoint Molecular Targeting","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VMT-alpha-NET","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Viewpoint Molecular Targeting","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viewpoint Molecular Targeting \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viewpoint Molecular Targeting \/ Inapplicable"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"177-Lu EBTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Targeting Technologies \/ Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Targeting Technologies \/ Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products"},{"orgOrder":0,"company":"Healx","sponsor":"R42 Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"HLX-1502","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healx \/ R42 Group","highestDevelopmentStatusID":"6","companyTruncated":"Healx \/ R42 Group"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Calidi Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase I","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aura Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Virus-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Belzupacap Sarotalocan","moa":"HSPG","graph1":"Oncology","graph2":"Phase I","graph3":"Aura Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Aura Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aura Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Megalith Pharmaceuticals","sponsor":"Corbus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CRB-701","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Megalith Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Megalith Pharmaceuticals \/ Corbus Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Megalith Pharmaceuticals \/ Corbus Pharmaceuticals"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RAG-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RAG-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"RAG-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prokarium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ZH9","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Prokarium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prokarium \/ Inapplicable"},{"orgOrder":0,"company":"Prokarium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ZH9","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Prokarium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prokarium \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Oncology","graph2":"Phase I","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Binimetinib","moa":"||Class I HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ University of Colorado","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ University of Colorado"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Onkure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Binimetinib","moa":"||Class I HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Onkure","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Onkure"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Exarafenib","moa":"RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinnate Biopharma \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Pierre Fabre"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Certepetide","moa":"Alpha-5 integrin","graph1":"Oncology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lisata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genelux","sponsor":"ELIAS Animal Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"V-VET1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Genelux","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genelux \/ ELIAS Animal Health","highestDevelopmentStatusID":"6","companyTruncated":"Genelux \/ ELIAS Animal Health"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Bio Elpida","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Bio Elpida","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Bio Elpida"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Deaconess Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Deaconess Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Deaconess Research Institute"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Hospices Civils de Lyon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Hospices Civils de Lyon","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Hospices Civils de Lyon"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"BVX-0918","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biovaxys \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Biovaxys \/ Undisclosed"},{"orgOrder":0,"company":"Mendus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Vididencel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mendus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mendus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mendus \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"MUC16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"MUC16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"MUC16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"MUC16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3005","moa":"MUC16","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Infusion","sponsorNew":"Precigen \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Cantrixil","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Lonza Group \/ Oasmia Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Oasmia Pharmaceutical"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MCY-M11","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Inapplicable"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MCY-M11","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Inapplicable"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MCY-M11","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cantrixil","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Kazia Therapeutics \/ Oasmia Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Oasmia Pharmaceutical"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Microorganism","year":"2024","type":"Funding","leadProduct":"Igrelimogene Litadenorepvec","moa":"||TNF-alpha\/IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"TILT Biotherapeutics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"SoftBank Vision","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"AB-1015","moa":"CTLA-4x\/OX40","graph1":"Oncology","graph2":"Phase I","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ArsenalBio \/ SoftBank Vision","highestDevelopmentStatusID":"6","companyTruncated":"ArsenalBio \/ SoftBank Vision"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"ArsenalBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-1015","moa":"CTLA-4x\/OX40","graph1":"Oncology","graph2":"Phase I","graph3":"ArsenalBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ArsenalBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ArsenalBio \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AddaVax","moa":"||AMHR2","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"HS-20089","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansoh Pharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Hansoh Pharma \/ GSK"},{"orgOrder":0,"company":"Epsilogen","sponsor":"British Patient Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Epsilogen \/ British Patient Capital","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ British Patient Capital"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Novartis Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Epsilogen \/ Novartis Venture Fund","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Novartis Venture Fund"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Oncologie","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Oncologie","highestDevelopmentStatusID":"6","companyTruncated":"Mereo BioPharma Group \/ Oncologie"},{"orgOrder":0,"company":"Innovate Biopharmaceuticals","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Innovate Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innovate Biopharmaceuticals \/ UK Government","highestDevelopmentStatusID":"6","companyTruncated":"Innovate Biopharmaceuticals \/ UK Government"},{"orgOrder":0,"company":"Qiagen","sponsor":"OncXerna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Navicixizumab","moa":"DLL4\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Qiagen \/ OncXerna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Qiagen \/ OncXerna Therapeutics"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enitociclib","moa":"||PTEFb\/CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SL-172154","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SL-172154","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shattuck Labs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-1607","moa":"CBL","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-1607","moa":"CBL","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NX-1607","moa":"CBL","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"iCamuno","sponsor":"I Peace","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"iCamuno","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"iCamuno \/ I Peace","highestDevelopmentStatusID":"6","companyTruncated":"iCamuno \/ I Peace"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"Greenfire Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GRN-300","moa":"||SIK2\/SIK3","graph1":"Oncology","graph2":"Phase I","graph3":"Greenfire Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Greenfire Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Greenfire Bio \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Volastra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Sovilnesib","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Amgen Inc \/ Volastra Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Volastra Therapeutics"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Serabelisb","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I","graph3":"Faeth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Faeth Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Faeth Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"A2A Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AO-252","moa":"TACC3","graph1":"Oncology","graph2":"Phase I","graph3":"A2A Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"A2A Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"A2A Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Sovilnesib","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Volastra Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"6","companyTruncated":"Volastra Therapeutics \/ Polaris Partners"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ Inapplicable"},{"orgOrder":0,"company":"Transgene","sponsor":"IUCT-Oncopole","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transgene \/ IUCT-Oncopole","highestDevelopmentStatusID":"6","companyTruncated":"Transgene \/ IUCT-Oncopole"},{"orgOrder":0,"company":"BostonGene","sponsor":"Transgene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"BostonGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BostonGene \/ Transgene","highestDevelopmentStatusID":"6","companyTruncated":"BostonGene \/ Transgene"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"De-TIL-0255","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"PhotonPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Autologous Cellular-Based Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PhotonPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PhotonPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PhotonPharma \/ Inapplicable"},{"orgOrder":0,"company":"PhotonPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Autologous Cellular-Based Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"PhotonPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PhotonPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PhotonPharma \/ Undisclosed"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Brenetafusp","moa":"PRAME","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"68-Ga Trivehexin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Radiopharm Theranostics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Inapplicable"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2021","type":"Acquisition","leadProduct":"Gemcitabine","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"VCN Biosciences \/ Grifols International","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Grifols International"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ Inapplicable"},{"orgOrder":0,"company":"Nanobiotix","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hafnium Oxide","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Nanobiotix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Nanobiotix \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Nanobiotix \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Takara Bio","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Microorganism","year":"2021","type":"Termination","leadProduct":"Canerpaturev","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Takara Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Takara Bio \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Takara Bio \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Tubepharma","sponsor":"Oncomatryx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody-drug Conjugate","year":"2023","type":"Acquisition","leadProduct":"OMTX705","moa":"||FAP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Tubepharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Tubepharma \/ Oncomatryx","highestDevelopmentStatusID":"6","companyTruncated":"Tubepharma \/ Oncomatryx"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"SN BioScience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"SN BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SN BioScience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SN BioScience \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Aveo Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"||HGF IgG1","graph1":"Oncology","graph2":"Phase I","graph3":"Aveo Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aveo Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aveo Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Surface Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Surface Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Surface Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Surface Oncology \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CDX-1140","moa":"||Dectin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiberCell \/ Celldex Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Celldex Therapeutics"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"||WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Misetionamide","moa":"||LPS","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Panavance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Misetionamide","moa":"||LPS","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Panavance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panavance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Misetionamide","moa":"||LPS","graph1":"Oncology","graph2":"Phase I","graph3":"Panavance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Panavance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Panavance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SY-5609","moa":"||CDK7","graph1":"Oncology","graph2":"Phase I","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syros Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syros Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IM156","moa":"||Protein complex-1","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoMet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMet \/ Inapplicable"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WNT974","moa":"||Porcupine","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Craig-Hallum Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Craig-Hallum Capital Group","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Craig-Hallum Capital Group"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diethyl Dihydroxyhomospermine","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Sun BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ivospemin","moa":"||Polyamine metabolic","graph1":"Oncology","graph2":"Phase I","graph3":"Sun BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sun BioPharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sun BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Avelumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Infusion","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"6","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"NGM Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NGM438","moa":"||LAIR-1","graph1":"Oncology","graph2":"Phase I","graph3":"NGM Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGM Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NGM Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Demelle","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Farnesyl-Di-Methyl-Chromanol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moffitt Cancer Center \/ Demelle","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Cancer Center \/ Demelle"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"Biomotion Sciences","sponsor":"Silexion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Merger","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Phase I","graph3":"Biomotion Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomotion Sciences \/ Silexion Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Biomotion Sciences \/ Silexion Therapeutics"},{"orgOrder":0,"company":"NovaRock Biotherapeutics","sponsor":"Flame Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"NBL-015","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"NovaRock Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaRock Biotherapeutics \/ Flame Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"NovaRock Biotherapeutics \/ Flame Biosciences"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Lantheus Holding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Private Placement","leadProduct":"68-Ga Trivehexin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiopharm Theranostics \/ Lantheus Holding","highestDevelopmentStatusID":"6","companyTruncated":"Radiopharm Theranostics \/ Lantheus Holding"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BSK01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ac-225 Lintuzumab","moa":"||CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Actinium pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"MT-6402","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Templates","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Molecular Templates \/ BVF Partners","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Templates \/ BVF Partners"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valemetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Compugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"COM701","moa":"PVRIG","graph1":"Oncology","graph2":"Phase I","graph3":"Compugen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Compugen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Compugen \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Relay Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"RLY-2608","moa":"||PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Nextech","highestDevelopmentStatusID":"6","companyTruncated":"Relay Therapeutics \/ Nextech"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Epsilogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Inapplicable"},{"orgOrder":0,"company":"Epsilogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mov18 IgE","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Epsilogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Epsilogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epsilogen \/ Inapplicable"},{"orgOrder":0,"company":"OnCusp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"CUSP06","moa":"CDH6","graph1":"Oncology","graph2":"Phase I","graph3":"OnCusp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OnCusp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OnCusp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SCB-313","moa":"Apoptosis","graph1":"Oncology","graph2":"Phase I","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Mabwell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"MWTX-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Mabwell","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Mabwell"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MWTX-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"MWTX-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"9MW3011","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mabwell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabwell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mabwell \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immunocore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"IMC-P115C","moa":"PRAME\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Immunocore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunocore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunocore \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"Immatics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"IMA203","moa":"||CD8-alpha-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immatics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Jefferies"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venetoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"St. Jude Children \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children \/ AbbVie Inc"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC007g","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GC007g","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2020","type":"Funding","leadProduct":"131-I Apamistamab","moa":"||CD45","graph1":"Oncology","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Goldman Sachs Alternatives","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"AJ1-11095","moa":"JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ajax Therapeutics \/ Goldman Sachs Alternatives","highestDevelopmentStatusID":"6","companyTruncated":"Ajax Therapeutics \/ Goldman Sachs Alternatives"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AJ1-11095","moa":"JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ajax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ajax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AJ1-11095","moa":"JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"Ajax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ajax Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ajax Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TP-3654","moa":"PIM","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Alpha Tau Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Radium-224","moa":"Alpha-radiation","graph1":"Oncology","graph2":"Phase I","graph3":"Alpha Tau Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Alpha Tau Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Tau Medical \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"FOR46","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"P-PSMA-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"P-PSMA-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"P-PSMA-101","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ADXS-504","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ADXS-504","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Ayala Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ADXS-504","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ayala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ayala Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ayala Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"SAKK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Oasmia Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oasmia Pharmaceutical \/ SAKK","highestDevelopmentStatusID":"6","companyTruncated":"Oasmia Pharmaceutical \/ SAKK"},{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","sponsor":"FutureChem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"177-Ludotadipep","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem","highestDevelopmentStatusID":"6","companyTruncated":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lorigerlimab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MacroGenics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MacroGenics \/ Inapplicable"},{"orgOrder":0,"company":"GEMoaB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"UniCAR-T-PSMA","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"GEMoaB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GEMoaB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GEMoaB \/ Inapplicable"},{"orgOrder":0,"company":"Teneobio","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Teneobio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Teneobio \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Teneobio \/ Amgen Inc"},{"orgOrder":0,"company":"Teneobio","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"TNB-585","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Teneobio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Teneobio \/ Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Teneobio \/ Amgen Inc"},{"orgOrder":0,"company":"SpectronRx","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Partnership","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SpectronRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SpectronRx \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"SpectronRx \/ ARTBIO"},{"orgOrder":0,"company":"PharmaLogic","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Agreement","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PharmaLogic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PharmaLogic \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"PharmaLogic \/ ARTBIO"},{"orgOrder":0,"company":"ARTBIO","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2023","type":"Financing","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ARTBIO \/ F-Prime Capital","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ F-Prime Capital"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Radiolabelled Compounds","year":"2023","type":"Series A Financing","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ARTBIO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ARTBIO \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"ARTBIO \/ Third Rock Ventures"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||PSCA","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-105","moa":"PSCA","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nucleus RadioPharma","sponsor":"ARTBIO","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Collaboration","leadProduct":"212-Pb NG001","moa":"ACE2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Nucleus RadioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nucleus RadioPharma \/ ARTBIO","highestDevelopmentStatusID":"6","companyTruncated":"Nucleus RadioPharma \/ ARTBIO"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2021","type":"Inapplicable","leadProduct":"64-Cu DOTA-TLX592","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cirtuvivint","moa":"||CLK\/DYRK","graph1":"Oncology","graph2":"Phase I","graph3":"Biosplice","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biosplice \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biosplice \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ORIC-944","moa":"Polycomb repressive complex-2","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORIC-944","moa":"Polycomb repressive complex-2","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"ORIC-101","moa":"||Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Griffith University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DpC","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Griffith University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Griffith University \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Griffith University \/ Inapplicable"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emtora Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Peter MacCallum Cancer Centre","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Peter MacCallum Cancer Centre","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Peter MacCallum Cancer Centre"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senhwa Biosciences","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pidnarulex","moa":"||PARP","graph1":"Oncology","graph2":"Phase I","graph3":"Senhwa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Senhwa Biosciences \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Senhwa Biosciences \/ Pfizer Inc"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pocenbrodib","moa":"CBP\/p300","graph1":"Oncology","graph2":"Phase I","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"IMU-935","moa":"ROR-gamma","graph1":"Oncology","graph2":"Phase I","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Immunic Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"6","companyTruncated":"Immunic Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Hinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ Inapplicable"},{"orgOrder":0,"company":"Hinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"HP518","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Hinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hinova \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AC0176","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AC0176","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"AccutarBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AC0176","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AccutarBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AccutarBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AccutarBio \/ Inapplicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"ONConcept Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Nanoform \/ ONConcept Consortium","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ ONConcept Consortium"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Inapplicable"},{"orgOrder":0,"company":"Ultimovacs","sponsor":"Oslo University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tendu","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ultimovacs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ultimovacs \/ Oslo University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Ultimovacs \/ Oslo University Hospital"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2024","type":"Partnership","leadProduct":"225-Ac PSMA-RADmAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Prosperity7 Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Prosperity7 Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Prosperity7 Ventures"},{"orgOrder":0,"company":"Oxford Vacmedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"OVM-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Vacmedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Vacmedix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Vacmedix \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Osanetant","moa":"NK-3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CTT1403","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Targeted Technology \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Targeted Technology \/ National Institutes of Health"},{"orgOrder":0,"company":"Illuminare Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Illuminare-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Illuminare Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Illuminare Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Illuminare Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"225-Ac PSMA-RADmAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"P-300","moa":"CREBBP\/EP300","graph1":"Oncology","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novo Nordisk \/ Pathos","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Pathos"},{"orgOrder":0,"company":"Kangpu Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Abiraterone","moa":"||CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Kangpu Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kangpu Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kangpu Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ciforadenant","moa":"||A2AR","graph1":"Oncology","graph2":"Phase I","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corvus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syncromune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SV-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syncromune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Syncromune \/ Inapplicable"},{"orgOrder":0,"company":"Syncromune","sponsor":"Williams Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SV-102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Syncromune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syncromune \/ Williams Cancer Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Syncromune \/ Williams Cancer Foundation"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Full-Life Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"225-Ac FL-020","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Full-Life Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Full-Life Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Full-Life Technologies \/ Inapplicable"},{"orgOrder":0,"company":"ANGLE plc","sponsor":"Crescendo Biologics Ltd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"CB307","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ANGLE plc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ANGLE plc \/ Crescendo Biologics Ltd","highestDevelopmentStatusID":"6","companyTruncated":"ANGLE plc \/ Crescendo Biologics Ltd"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CB307","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Crescendo Biologics Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crescendo Biologics Ltd \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crescendo Biologics Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Financing","leadProduct":"CB307","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Crescendo Biologics Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crescendo Biologics Ltd \/ Sofinnova Partners","highestDevelopmentStatusID":"6","companyTruncated":"Crescendo Biologics Ltd \/ Sofinnova Partners"},{"orgOrder":0,"company":"Black Diamond Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"BDTX-4933","moa":"RAS\/RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Black Diamond Therapeutics","amount2":0.78000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.78000000000000003,"dosageForm":"Oral","sponsorNew":"Black Diamond Therapeutics \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Black Diamond Therapeutics \/ Servier"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Asymchem Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"AUM601","moa":"TRKA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Asymchem Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ Asymchem Laboratories"},{"orgOrder":0,"company":"Erasca","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erasca \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ J.P. Morgan"},{"orgOrder":0,"company":"Erasca","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ BofA Securities"},{"orgOrder":0,"company":"Erasca","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"Nested Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NST-628","moa":"Pan-RAF\/MEK","graph1":"Oncology","graph2":"Phase I","graph3":"Nested Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nested Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nested Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ABM Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ABM-168","moa":"MEK receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ABM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ABM Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABM Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EQRx","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"RMC-6236","moa":"RAS","graph1":"Oncology","graph2":"Phase I","graph3":"EQRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EQRx \/ Revolution Medicines","highestDevelopmentStatusID":"6","companyTruncated":"EQRx \/ Revolution Medicines"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"123-I ATT001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"EVM16","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"EVM16","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Everest Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Erasca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||Pan-RAF","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Erasca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Inapplicable"},{"orgOrder":0,"company":"Allarity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Stenoparib","moa":"||PARP-1","graph1":"Oncology","graph2":"Phase I","graph3":"Allarity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allarity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allarity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Immatics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"IMA401","moa":"MAGE-A4\/8","graph1":"Oncology","graph2":"Phase I","graph3":"Immatics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immatics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Immatics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sovilnesib","moa":"KIF18A","graph1":"Oncology","graph2":"Phase I","graph3":"Volastra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Volastra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Volastra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HF1K16","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VCN-01","moa":"Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VCN-01","moa":"Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"Ionctura","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Roginolisib","moa":"||PI3K delta","graph1":"Oncology","graph2":"Phase I","graph3":"Ionctura","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ionctura \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ionctura \/ Inapplicable"},{"orgOrder":0,"company":"GT Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"GTB-3650","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"GT Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GT Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GT Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"BP1002","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Inapplicable"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":1,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Intravenous Injection","sponsorNew":"EsoBiotec \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ AstraZeneca"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVA-001","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Inapplicable"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVA-001","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Inapplicable"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CTA101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioheng Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Alemtuzumab","moa":"||CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Cellectis","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Cellectis"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GC019F","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SGR-1505","moa":"MALT1","graph1":"Oncology","graph2":"Phase I","graph3":"Schrodinger","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Schrodinger \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Schrodinger \/ Inapplicable"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interius BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Interius BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Notable Labs \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Notable Labs \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BG1805","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Guangzhou Bio-gene Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Guangzhou Bio-gene Technology \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vincerx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"VIP943","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Vincerx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vincerx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vincerx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BP1002","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"MEI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Voruciclib","moa":"||CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"MEI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MEI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MEI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CB-012","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cytarabine","moa":"||CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PRGN-3006","moa":"CD33","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precigen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Inapplicable"},{"orgOrder":0,"company":"HiberCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HC-7366","moa":"||GCN2","graph1":"Oncology","graph2":"Phase I","graph3":"HiberCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HiberCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiberCell \/ Inapplicable"},{"orgOrder":0,"company":"SystImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BL-M11D1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SystImmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SystImmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SystImmune \/ Inapplicable"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"\u00daHKT","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CAR123","moa":"CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied DNA Sciences Inc \/ \u00daHKT","highestDevelopmentStatusID":"6","companyTruncated":"Applied DNA Sciences Inc \/ \u00daHKT"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"AVC-101","moa":"||CD123","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AvenCell Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"HG-CT-1","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fate Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bantam Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BTM-3566","moa":"HRI Kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Bantam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Bantam Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bantam Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SynKIR-310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verismo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"KJ-C2219","moa":"CD19\/20","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SIRPant Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SI-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SIRPant Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"SIRPant Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SIRPant Immunotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LP-284","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Blue Owl Capital","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Blue Owl Capital"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Marker Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Neldaleucel","moa":"WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Marker Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Marker Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Marker Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"NKX019","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nkarta Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Adage Capital Partners"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CD19 t-haNK","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunityBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ Inapplicable"},{"orgOrder":0,"company":"Sellas Life Sciences Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Galinpepimut-S","moa":"||WT1","graph1":"Oncology","graph2":"Phase I","graph3":"Sellas Life Sciences Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sellas Life Sciences Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sellas Life Sciences Group \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":1.5,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"P-BCMA-ALLO1","moa":"||BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Poseida Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Poseida Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poseida Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"EsoBiotec","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"EsoBiotec","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"EsoBiotec \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EsoBiotec \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORIC-533","moa":"CD73","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Opna Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Opna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Opna Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Opna Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Opna Bio \/ Inapplicable"},{"orgOrder":0,"company":"Wistar Institute of Anatomy and Biology","sponsor":"Active Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Tasquinimod","moa":"||S100A9","graph1":"Oncology","graph2":"Phase I","graph3":"Wistar Institute of Anatomy and Biology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Wistar Institute of Anatomy and Biology \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Wistar Institute of Anatomy and Biology \/ Active Biotech"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Indapta Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"IDP-023","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indapta Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Indapta Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"SIM0500","moa":"GPRC5D\/BCMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Simcere Pharmaceutical","amount2":1.0600000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":1.0600000000000001,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ AbbVie Inc"},{"orgOrder":0,"company":"Aurigene Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Ribrecabtagene Autoleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aurigene Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurigene Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aurigene Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Descartes-15","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cartesian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartesian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cartesian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"Certara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"ISB 2001","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ichnos Glenmark Innovation \/ Certara","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Glenmark Innovation \/ Certara"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Private Placement","leadProduct":"PYX-201","moa":"Fibronectin EDB","graph1":"Oncology","graph2":"Phase I","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Pyxis Oncology \/ Deep Track Capital"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Auristatin","moa":"||Fibronectin EDB","graph1":"Oncology","graph2":"Phase I","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DFP-14927","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta-Fly Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delta-Fly Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"JANX008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"JANX008","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Abraxane","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"VCN Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"VCN Biosciences \/ Theriva Biologics","highestDevelopmentStatusID":"6","companyTruncated":"VCN Biosciences \/ Theriva Biologics"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VCN-01","moa":"Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Topotecan","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Oncoheroes Biosciences Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Volasertib","moa":"PLK1","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ Oncoheroes Biosciences Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Notable Labs \/ Oncoheroes Biosciences Inc."},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LYL797","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyell Immunopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Camsirubicin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"GenScript Biotech Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TAEST16001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ GenScript Biotech Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue Life Sciences \/ GenScript Biotech Corporation"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Doxorubicin Prodrug","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Inapplicable"},{"orgOrder":0,"company":"Curadev Pharma Private Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CRD3874-SI","moa":"STING","graph1":"Oncology","graph2":"Phase I","graph3":"Curadev Pharma Private Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curadev Pharma Private Limited \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Curadev Pharma Private Limited \/ Inapplicable"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"TCG GreenChem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shuttle Pharmaceuticals \/ TCG GreenChem","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ TCG GreenChem"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Syena","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SY-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Syena","highestDevelopmentStatusID":"6","companyTruncated":"National Institutes of Health \/ Syena"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"SON-1010","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Idronoxil","moa":"||cGAS-STING signaling pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noxopharm \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TP-1287","moa":"CDK9","graph1":"Oncology","graph2":"Phase I","graph3":"Sumitomo Pharma Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sumitomo Pharma Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sumitomo Pharma Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"INBRX-109","moa":"||DR5","graph1":"Oncology","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||NY-ESO-1","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ GSK"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2023","type":"Inapplicable","leadProduct":"FHD-609","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"PROTACs","year":"2022","type":"Inapplicable","leadProduct":"FHD-609","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LB2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"LB2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Legend Biotech","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"LB2102","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Legend Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Legend Biotech \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Legend Biotech \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ariceum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu Satoreotide Tetraxetan","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ariceum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ariceum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ariceum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Ariceum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"177Lu-Satoreotide Tetraxetan","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Eckert & Ziegler Strahlen \/ Ariceum Therapeutics"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Windtree Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Windtree Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Windtree Therapeutics"},{"orgOrder":0,"company":"Ascentage Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pelcitoclax","moa":"BCL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Ascentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ascentage Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascentage Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ City of Hope"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LB-100","moa":"||PP2A","graph1":"Oncology","graph2":"Phase I","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA","moa":"||GD2","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Akeso","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||PD-1\/VEGF","graph1":"Oncology","graph2":"Phase I","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Akeso \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akeso \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ZL-1310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"ZL-1310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zai Lab \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"177-Lu Minigastrin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Debiopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Debiopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Debiopharm \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Large Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"OBT620","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Evergreen Theragnostics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"68-Ga EVG321","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Evergreen Theragnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evergreen Theragnostics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evergreen Theragnostics \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PRT3789","moa":"SMARCA2","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Docetaxel","moa":"||SMARCA2","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"PRT3789","moa":"SMARCA2","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prelude Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Shattuck Labs","sponsor":"Evercore ISI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Private Placement","leadProduct":"SL-172154","moa":"CD47-SIRPalpha","graph1":"Oncology","graph2":"Phase I","graph3":"Shattuck Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Shattuck Labs \/ Evercore ISI","highestDevelopmentStatusID":"6","companyTruncated":"Shattuck Labs \/ Evercore ISI"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cytokine Induced Memory-Like Natural Killer Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImmunityBio \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"ImmunityBio \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"OSE Immunotherapeutics SA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"BI 765063","moa":"||SIRP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"OSE Immunotherapeutics SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"OSE Immunotherapeutics SA \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F-star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"F-star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F-star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"F-star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series C Financing","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Bicara Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ficerafusp Alpha","moa":"||EGFR\/TGF-beta","graph1":"Oncology","graph2":"Phase I","graph3":"Bicara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bicara Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Bicara Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Theriva Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Hyaluronidase","graph1":"Oncology","graph2":"Phase I","graph3":"Theriva Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theriva Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theriva Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Boundless Bio","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series C Financing","leadProduct":"BBI-355","moa":"CHK-1","graph1":"Oncology","graph2":"Phase I","graph3":"Boundless Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Boundless Bio \/ Leaps by Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Boundless Bio \/ Leaps by Bayer"},{"orgOrder":0,"company":"BostonGene","sponsor":"Transgene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Expanded Collaboration","leadProduct":"TG4050","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"BostonGene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BostonGene \/ Transgene","highestDevelopmentStatusID":"6","companyTruncated":"BostonGene \/ Transgene"},{"orgOrder":0,"company":"Coherus Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Toripaliamab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Coherus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coherus Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coherus Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PBA-0405","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xencor \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BI 770371","moa":"||SIRP-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ OSE Immunotherapeutics SA"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Kiromic BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deltacel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Kiromic BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kiromic BioPharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kiromic BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase I","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase I","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ Moffitt Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Panbela Therapeutics \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"AB011","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CARsgen Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PT886","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phanes Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Phanes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Phanes Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Phanes Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Trishula Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ttx-030","moa":"||CD39","graph1":"Oncology","graph2":"Phase I","graph3":"Trishula Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Trishula Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Trishula Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Bioheng Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTB001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Bioheng Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bioheng Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioheng Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Connoya Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Connoya Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"KYM Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"KYM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KYM Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"KYM Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"KYM Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"CMG901","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"KYM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KYM Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"KYM Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"ALX Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Evorpacept","moa":"||CD47","graph1":"Oncology","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eli Lilly \/ ALX Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ ALX Oncology"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"HFB200301","moa":"||TNF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiFiBiO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HiFiBiO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"HFB200301","moa":"||TNF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"HiFiBiO Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Elevation Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Licensing Agreement","leadProduct":"EO-3021","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSPC Pharmaceutical Group \/ Elevation Oncology","highestDevelopmentStatusID":"6","companyTruncated":"CSPC Pharmaceutical Group \/ Elevation Oncology"},{"orgOrder":0,"company":"RemeGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"RC118","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Inapplicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ACE1702","moa":"||HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"||IL-7 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Merck Group \/ Genome & Company","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Genome & Company"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"ATG-022","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CLDN18.2\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CLDN18.2\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CLDN18.2\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"OBI Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OBI-3424","moa":"||AKR1C3","graph1":"Oncology","graph2":"Phase I","graph3":"OBI Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OBI Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OBI Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Signet","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"sigx1094","moa":"FAK\/YAP","graph1":"Oncology","graph2":"Phase I","graph3":"Signet","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signet \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Signet \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fenretinide","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"SciTech Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fenretinide","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech Development","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech Development \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech Development \/ Inapplicable"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"IRELAND","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Emactuzumab","moa":"CSF-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SynOx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SynOx Therapeutics \/ Healthcaps India","highestDevelopmentStatusID":"6","companyTruncated":"SynOx Therapeutics \/ Healthcaps India"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AIC100","moa":"ICAM-1","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffyImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"ORI Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"AIC100","moa":"ICAM-1","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffyImmune Therapeutics \/ ORI Capital","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune Therapeutics \/ ORI Capital"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Weill Cornell Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AIC100","moa":"ICAM-1","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffyImmune Therapeutics \/ Weill Cornell Medicine","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune Therapeutics \/ Weill Cornell Medicine"},{"orgOrder":0,"company":"Sotio","sponsor":"Cytune Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CZECH REPUBLIC","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-15 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sotio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sotio \/ Cytune Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Sotio \/ Cytune Pharma"},{"orgOrder":0,"company":"AffyImmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AIC100","moa":"ICAM-1","graph1":"Oncology","graph2":"Phase I","graph3":"AffyImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AffyImmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AffyImmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RP-1664","moa":"PLK4","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RP-1664","moa":"PLK4","graph1":"Oncology","graph2":"Phase I","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Repare Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Repare Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atreca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ATRC-101","moa":"||RNP complex","graph1":"Oncology","graph2":"Phase I","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Atreca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atreca \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"CF33-hNIS-antiPDL1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"City of Hope \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Valo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OncoNano Medicine","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Cemiplimab","moa":"||STING","graph1":"Oncology","graph2":"Phase I","graph3":"OncoNano Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"OncoNano Medicine \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"OncoNano Medicine \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"AMHR2","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Hummingbird Bioscience","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"HMBD-002","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Hummingbird Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hummingbird Bioscience \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Hummingbird Bioscience \/ Merck & Co"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Italian Angels for Growth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Series A Financing","leadProduct":"PEP-010","moa":"Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Italian Angels for Growth","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Italian Angels for Growth"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Anaxago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Series A Financing","leadProduct":"PEP-010","moa":"Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Anaxago","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Anaxago"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"PEP-010","moa":"Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mersana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Emiltatug Ledadotin","moa":"B7-H4","graph1":"Oncology","graph2":"Phase I","graph3":"Mersana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mersana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mersana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Theratechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide-drug Conjugate","year":"2021","type":"Collaboration","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Piramal Pharma Solutions \/ Theratechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Pharma Solutions \/ Theratechnologies"},{"orgOrder":0,"company":"NBE-Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Series C Financing","leadProduct":"NBE-002","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NBE-Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NBE-Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"NBE-Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"NBE-Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"NBE-002","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"NBE-Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NBE-Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"NBE-Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Merck & Co","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Olinvacimab","moa":"||VEGF2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Merck & Co \/ PharmAbcine","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ PharmAbcine"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anixa Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Codagenix","sponsor":"Adjuvant Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Codagenix \/ Adjuvant Capital","highestDevelopmentStatusID":"6","companyTruncated":"Codagenix \/ Adjuvant Capital"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cleveland Clinic \/ Anixa Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Cleveland Clinic \/ Anixa Biosciences"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Paxalisib","moa":"||PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"QIMR Berghofer Medical Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Paxalisib","moa":"PI3K\/AKT\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Kazia Therapeutics \/ QIMR Berghofer Medical Research Institute"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mifepristone","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"||IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Anixa Biosciences","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"Alpha-Lactalbumin-Based Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Anixa Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anixa Biosciences \/ Cleveland Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Anixa Biosciences \/ Cleveland Clinic"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lantern Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Irofulven","moa":"DNA adduct","graph1":"Oncology","graph2":"Phase I","graph3":"Lantern Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lantern Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lantern Pharma \/ Inapplicable"},{"orgOrder":0,"company":"UbiVac","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BMS-986178","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"UbiVac","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UbiVac \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"UbiVac \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AB011","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"Rodman & Renshaw LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"MNPR-101-Zr","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ Rodman & Renshaw LLC","highestDevelopmentStatusID":"6","companyTruncated":"Monopar Therapeutics \/ Rodman & Renshaw LLC"},{"orgOrder":0,"company":"Pyxis Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"PYX-106","moa":"Siglec-15","graph1":"Oncology","graph2":"Phase I","graph3":"Pyxis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pyxis Oncology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pyxis Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TARA-002","moa":"Th1","graph1":"Oncology","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravesical Liquid, Instillation","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"ATONCO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"89Zr-DFO-girentuximab","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Telix Pharmaceuticals \/ ATONCO","highestDevelopmentStatusID":"6","companyTruncated":"Telix Pharmaceuticals \/ ATONCO"},{"orgOrder":0,"company":"Asieris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APL-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Asieris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Asieris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asieris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FHD-286","moa":"Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FHD-286","moa":"||Allosteric ATPase","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Hyfinity Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InxMed \/ Hyfinity Investments","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Hyfinity Investments"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"InxMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ifebemtinib","moa":"||FAK","graph1":"Oncology","graph2":"Phase I","graph3":"InxMed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"InxMed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"InxMed \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"Toll-like-9 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"X4 Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavorixafor","moa":"||CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"X4 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"X4 Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"X4 Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-102","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Cue Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CUE-102","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Cue Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cue Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cue Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pliant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||Alpha-5-beta-1\/Alpha-5-beta-8","graph1":"Oncology","graph2":"Phase I","graph3":"Pliant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pliant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pliant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bexobrutideg","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nurix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Oncology Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BBO-11818","moa":"||KRASG12D\/KRASG12V","graph1":"Oncology","graph2":"Phase I","graph3":"BridgeBio Oncology Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Oncology Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Oncology Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CLD-101","moa":"CRAd-S-pk7","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Calidi Biotherapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ City of Hope"},{"orgOrder":0,"company":"Pheast Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"PHST001","moa":"CD24","graph1":"Oncology","graph2":"Phase I","graph3":"Pheast Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pheast Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pheast Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Toragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||E5 oncogene protein","graph1":"Oncology","graph2":"Phase I","graph3":"Toragen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Toragen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Toragen \/ Inapplicable"},{"orgOrder":0,"company":"Kairos Pharma","sponsor":"U S Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Funding","leadProduct":"Carotuximab","moa":"||ENG","graph1":"Oncology","graph2":"Phase I","graph3":"Kairos Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kairos Pharma \/ U S Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Kairos Pharma \/ U S Department of Defense"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CT-95","moa":"MSLN\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Radiance Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"RB-164","moa":"ROR1 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Radiance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radiance Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radiance Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Mipletamig","moa":"CD23\/CD123","graph1":"Oncology","graph2":"Phase I","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Aptevo Therapeutics \/ Jade Biosciences"},{"orgOrder":0,"company":"Sichuan Kelun-Biotech Biopharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"SKB518","moa":"PTK7","graph1":"Oncology","graph2":"Phase I","graph3":"Sichuan Kelun-Biotech Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sichuan Kelun-Biotech Biopharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"89Zr-Olaratumab","moa":"PDGF receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Telix Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jabez Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"JBZ-001","moa":"DHODH","graph1":"Oncology","graph2":"Phase I","graph3":"Jabez Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jabez Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jabez Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Clasp Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"CLSP-1025","moa":"p53 R175H","graph1":"Oncology","graph2":"Phase I","graph3":"Clasp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clasp Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Clasp Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IBI3020","moa":"CEACAM5","graph1":"Oncology","graph2":"Phase I","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"SciTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fenretinide","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"SciTech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SciTech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SciTech \/ Inapplicable"},{"orgOrder":0,"company":"HighField Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"HighField Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"HighField Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HighField Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BrainChild Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BCB-276","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"BrainChild Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"BrainChild Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BrainChild Bio \/ Inapplicable"},{"orgOrder":0,"company":"Y-mAbs Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"177-Lu DOTA","moa":"||CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Y-mAbs Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Y-mAbs Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Y-mAbs Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Delcath Systems","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Melphalan Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-arterial Infusion","sponsorNew":"Delcath Systems \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Delcath Systems \/ Inapplicable"},{"orgOrder":0,"company":"Senti Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cytarabine","moa":"||CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Senti Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Senti Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Senti Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"225-Ac GPC3","moa":"GPC3","graph1":"Oncology","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Ingenium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Gengleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ingenium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ingenium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ingenium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"ISB 2001","moa":"BCMA\/CD38\/CD3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ichnos Glenmark Innovation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Glenmark Innovation \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Janux Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"JANX007","moa":"PSMA\/CD3","graph1":"Oncology","graph2":"Phase I","graph3":"Janux Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Janux Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Janux Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adcentrx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"ADRX-0706","moa":"Nectin-4","graph1":"Oncology","graph2":"Phase I","graph3":"Adcentrx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adcentrx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adcentrx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ideaya Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"IDE849","moa":"DLL3\/TOP1","graph1":"Oncology","graph2":"Phase I","graph3":"Ideaya Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ideaya Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ideaya Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"PAQ Therapeutics","sponsor":"Bayland Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"PT0253","moa":"KRAS G12D","graph1":"Oncology","graph2":"Phase I","graph3":"PAQ Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"PAQ Therapeutics \/ Bayland Capital","highestDevelopmentStatusID":"6","companyTruncated":"PAQ Therapeutics \/ Bayland Capital"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CT0596","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CARsgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Public Offering","leadProduct":"CX-2051","moa":"EpCAM","graph1":"Oncology","graph2":"Phase I","graph3":"CytomX Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"CytomX Therapeutics \/ OrbiMed","highestDevelopmentStatusID":"6","companyTruncated":"CytomX Therapeutics \/ OrbiMed"},{"orgOrder":0,"company":"Remedy Plan Therapeutics","sponsor":"Schooner Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"RPT1G","moa":"NAMPT","graph1":"Oncology","graph2":"Phase I","graph3":"Remedy Plan Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Remedy Plan Therapeutics \/ Schooner Capital","highestDevelopmentStatusID":"6","companyTruncated":"Remedy Plan Therapeutics \/ Schooner Capital"}]

    Find Oncology Drugs in Phase I Clinical Development

    cayman pipeline prospector

    Virtual Booth

    Contact Supplier

    Check COS database
    Check USDMF database

    Contact Us
    PharmaScopic.com

    Click to view the API/FDF
    Pricing Demo Dashboard
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            BioProcess International Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-CLS-484,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Calico Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhib...

                            Details : ABBV-CLS-484 is the first active-site phosphatase inhibitor to enter clinical evaluation as a cancer therapy and is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors.

                            Product Name : ABBV-CLS-484

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 10, 2023

                            Lead Product(s) : ABBV-CLS-484,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Calico Life Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Quotient Sciences

                            United Kingdom
                            CPhI North America
                            Booth #1220
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : OXL001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Oxilio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Oxilio Announces Start of Its First Clinical Trial With OXL001

                            Details : OXL001, has been developed utilising a novel bio-enabling platform technology, it has been taken into clinical studies which gives its immense potential as a pan-cancer therapy.

                            Product Name : OXL001

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 11, 2022

                            Lead Product(s) : OXL001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Oxilio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Isatuximab,Dexamethasone,Pomalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $330.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi Announces €300 Million Collaboration with Blackstone Life Sciences to Advance an Innovative Treatment...

                            Details : For the Sarclisa® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company to advance the development of a subcutaneous delivery for Sarclisa® with the goal of offering a unique patient-centric treatment e...

                            Product Name : Sarclisa

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 15, 2022

                            Lead Product(s) : Isatuximab,Dexamethasone,Pomalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $330.0 million

                            Deal Type : Collaboration

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : UCART22,Alemtuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cellectis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cellectis and Sanofi Partner on Alemtuzumab as Lymphodepletion Agent for Allogeneic CAR-T

                            Details : In Cellectis sponsored trials, alemtuzumab is currently used as part of the lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial in relapsed/refractory ALL, and for UCART123 in the AMELI-01 clinical trial in relapsed/refractory AML, but not...

                            Product Name : UCART22

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 05, 2021

                            Lead Product(s) : UCART22,Alemtuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cellectis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Axplora

                            Germany
                            CPhI North America
                            Booth #1145
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAxplora is your partner of choice for complex APIs.

                            Lead Product(s) : XB002,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Exelixis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Novasep Secures Manufacturing Deal with US Biotech for ADC Drug Candidate

                            Details : Through the agreement, Novosep will perform the process development of the XB002 ADC. which is being evaluated in the early-stage clinical trial studies for the treatment of non-small cell lung cancer and cervical cancer.

                            Product Name : XB002

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            July 07, 2021

                            Lead Product(s) : XB002,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Exelixis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Axplora CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Natural Killer Cell,Filgrastim,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kiadis Pharma announces new data on ex-vivo FC21

                            Details : The abstract showcases the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML).

                            Product Name : KDS-1001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            October 03, 2020

                            Lead Product(s) : Natural Killer Cell,Filgrastim,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : K-NK003,Cytarabine,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kiadis Announces First Patient Enrolled in Clinical Study Conducted at The Ohio State University in R/R AML

                            Details : The trial is expected to provide further clinical proof-of-concept of Kiadis’ K-NK003 product.

                            Product Name : K-NK003

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            June 25, 2020

                            Lead Product(s) : K-NK003,Cytarabine,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : KD033

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kadmon Doses First Patient in Phase 1 Clinical Trial of KD033

                            Details : First patient has been dosed in a Phase 1 clinical trial evaluating KD033 in patients with metastatic or locally advanced solid tumors. KD033 is a novel immunotherapy designed to stimulate innate and adaptive immune responses directed to the tumor microe...

                            Product Name : KD033

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 23, 2020

                            Lead Product(s) : KD033

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Interleukin-21-Expanded Haploidentical Nk Cell,Cytarabine HCl,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kiadis Announces New Data Related To Its K-NK Cell Therapy Platform Presented today at the ASCO 2020 Virtual A...

                            Details : A poster presentation demonstrates results of multiple FC21-NK infusions in R/R AML patients with CNS disease, treated in an investigator-initiated Phase I/II study.

                            Product Name : mbIL21

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 29, 2020

                            Lead Product(s) : Interleukin-21-Expanded Haploidentical Nk Cell,Cytarabine HCl,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : K-NK003,Cytarabine,Decitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML

                            Details : The trial is expected to provide further clinical proof-of-concept of Kiadis’ K-NK003 product.

                            Product Name : K-NK003

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 26, 2020

                            Lead Product(s) : K-NK003,Cytarabine,Decitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth